Authors:

Lena Tschiderer (Medical University of Innsbruck)

Sanne Peters (University Medical Center Utrecht)

Yvonne van der Schouw (University Medical Center Utrecht)

Anniek van Westing (University Medical Center Utrecht)

Tammy Tong (University of Oxford)

Peter Willeit (Medical University of Innsbruck)

Lisa Seekircher (Medical University of Innsbruck)

Conchi Moreno Iribas (Instituto de Salud Pública de Navarra, Departamento de Salud, Gobierno de Navarra)

José María Huerta (Murcia Regional Health Council)

Marta Crous-Bou (Catalan Institute of Oncology (ICO) - Bellvitge Biomedical Research Institute (IDIBELL))

Martin Söderholm (Lund University)

Matthias Schulze (German Institute of Human Nutrition)

Cecilia Johansson (Umeå University)

Sara Själander (Umeå University)

Alicia Heath (Imperial College London)

Alessandra Macciotta (University of Turin)

Christina Dahm (Aarhus University)

Daniel Ibsen (Aarhus University)

Valeria Pala (Fondazione IRCCS Istituto Nazionale dei Tumori)

Lene Mellemkjær (Danish Cancer Society Research Center)

Stephen Burgess (University of Cambridge)

Angela Wood (Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care,

University of Cambridge, United Kingdom)

Rudolf Kaaks (German Cancer Research Center (DKFZ))

Verena Katzke (German Cancer Research Center (DKFZ))

Pilar Amiano (Ministry of Health of the Basque Government)

Miguel Rodríguez-Barranco (Escuela Andaluza de Salud Pública. Instituto de Investigación Biosanitaria

ibs.GRANADA, Universidad de Granada, Granada, Spain)

Gunnar Engström (Lund University)

Elisabete Weiderpass (International Agency for Research on Cancer)

Anne Tjønneland (Danish Cancer Society)

Jytte Halkjær (Danish Cancer Society Research Center)

Salvatore Panico (Università Federico II Napoli)

John Danesh (University of Cambridge)

Adam S. Butterworth (University of Cambridge)

N. Charlotte Onland-Moret (Julius Center for Health Sciences & Primary Care, University Medical Center, Utrecht)

Age at menopause and the risk of stroke: Observational and Mendelian Randomization analysis in 204,244 postmenopausal women

Lena Tschiderer, PhD,^{1,2} Sanne AE Peters, PhD,^{1,3,4} Yvonne T van der Schouw, PhD,¹ Anniek C van Westing, MSc,^{1,5} Tammy YN Tong, PhD,⁶ Peter Willeit, PhD,^{2,7} Lisa Seekircher, DI,² Conchi Moreno-Iribas, PhD,^{8,9,10} José María Huerta, PhD,^{11,9} Marta Crous-Bou, PhD,^{12,13} Martin Söderholm, PhD,^{14,15} Matthias B Schulze, DrPH,^{16,17} Cecilia Johansson, MD,¹⁸ Sara Själander, MD, PhD,¹⁹ Alicia K Heath, PhD,²⁰ Alessandra Macciotta, MSc,²¹ Christina C Dahm, PhD,²² Daniel B Ibsen, PhD,^{22,23,24,25} Valeria Pala, ScD,²⁶ Lene Mellemkjær, PhD,²⁷ Stephen Burgess, PhD,^{7,28,29} Angela Wood, PhD,⁷ Rudolf Kaaks, PhD,³⁰ Verena Katzke, PhD,³⁰ Pilar Amiano, PharmD, MSc,^{31,32,9} Miguel Rodriguez-Barranco, BSc, PhD,^{33,34,9} Gunnar Engström, PhD,¹⁵ Elisabete Weiderpass, PhD,³⁵Anne Tjønneland, MD, PhD, DMSc,^{27,36} Jytte Halkjær, PhD,²⁷ Salvatore Panico, MD,³⁷ John Danesh, PhD,^{38,39,40,41,42,43} Adam Butterworth, PhD,^{7,28,44,45,42} N Charlotte Onland-Moret, PhD¹

¹Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands; ²Institute of Health Economics, Medical University of Innsbruck, Innsbruck, Austria; ³The George Institute for Global Health, School of Public Health, Imperial College London, London, United Kingdom; ⁴The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia; ⁵Division of Human Nutrition and Health, Wageningen University, Wageningen, the Netherlands: 6Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, United Kingdom; ⁷Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 8Instituto de Salud Pública y Laboral de Navarra, 31003 Pamplona, Spain; 9Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain; ¹⁰Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Spain; ¹¹Department of Epidemiology, Murcia Regional Health Council-IMIB, Murcia, Spain: ¹²Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona 08908, Spain; ¹³Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; ¹⁴Department of Neurology, Skåne University Hospital, Lund and Malmö, Malmö, Sweden: ¹⁵Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden; ¹⁶Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany; ¹⁷Institute of **Nutritional** Science, University of Potsdam, Nuthetal, Germany; 18Skellefteå Research Unit, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Västerbotten, Sweden; ¹⁹Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; ²⁰Department of Epidemiology and Biostatistics, School of Public Health,

Epidemiology, and Public Health (C-BEPH), Department of Clinical and Biological Sciences, University of Turin, Turin, Italy; ²²Department of Public Health, Aarhus University, Aarhus, Denmark; ²³Steno Diabetes Center Aarhus, Aarhus, Denmark; ²⁴MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom; ²⁵Department of Nutrition, Exercise and Sports, University of Copenhagen, Frederiksberg, Denmark; ²⁶Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; ²⁷Danish Cancer Society Research Center, Strandboulevarden 49, 2100, Copenhagen, Denmark; ²⁸Heart and Lung Research Institute, University of Cambridge, Cambridge, United Kingdom; ²⁹MRC Biostatistics Unit, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom; ³⁰Division of Cancer Epidemiology, German Cancer Research Center, DKFZ, 69120 Heidelberg, Germany; ³¹Ministry of Health of the Basque Government, Sub Directorate for Public Health and Addictions of Gipuzkoa, San Sebastian, Spain; ³²Biodonostia Health Research Institute, Epidemiology of Chronic and Communicable Diseases Group, San Sebastian, Spain; ³³Escuela Andaluza de Salud Pública (EASP), 18011 Granada, Spain; ³⁴Instituto de Investigación Biosanitaria ibs.GRANADA, 18012 Granada, Spain; ³⁵International Agency for Research on Cancer, World Health Organization, Lyon, France; ³⁶Department of Public Health, Section of Environmental Health, Faculty of Health and Medical Sciences, University of Copenhagen, DK-1353 Copenhagen, Denmark; ³⁷School of Medicine, Federico II University, Naples, Italy; ³⁸BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; ³⁹National Institute for Health and Care Research Cambridge Biomedical Research Centre, Cambridge University Hospitals, Cambridge, United Kingdom; ⁴⁰The National Institute for Health and Care Research Blood and Transplant Unit (NIHR BTRU) in Donor Health and Genomics, University of Cambridge, Cambridge, United Kingdom; ⁴¹Human Genetics, Wellcome Sanger Institute, Saffron Walden, United Kingdom; ⁴²Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge, Cambridge, United Kingdom; ⁴³British Heart Foundation Centre of Research Excellence, Division of Cardiovascular Medicine, Addenbrooke's Hospital, Cambridge, United Kingdom; ⁴⁴NIHR Blood and Transplant Research Unit in Donor Health and Behaviour, University of Cambridge, Cambridge, United Kingdom; ⁴⁵BHF Centre of Research Excellence, School of Clinical Medicine, Addenbrooke's Hospital, Cambridge, United Kingdom

Short title: Age at menopause and the risk of stroke

Correspondence to:

Yvonne T van der Schouw

Julius Center for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands

Tel: +31 (0) 631118668; Email: y.t.vanderschouw@umcutrecht.nl

Word count: 4,848; 2 Tables; 3 Figures

Abstract

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Background: Observational studies have shown that women with an early menopause are at higher risk of stroke compared to women with a later menopause. However, associations with stroke subtypes are inconsistent and the causality is unclear. Therefore, we conducted a large-scale analysis to investigate the observational association between age at menopause and different types of stroke accompanied by a Mendelian Randomization analysis to evaluate causality. Methods: We analyzed data of the UK Biobank and EPIC-CVD study. Postmenopausal women without a history of stroke at baseline were eligible for inclusion. The study endpoints were total stroke and stroke subtypes (i.e., ischemic stroke, hemorrhagic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage). We investigated the observational association between age at menopause and risk of stroke using Cox-regression analysis in each study separately before combining effect sizes using random-effects meta-analysis. Cox-regression analyses were progressively adjusted for (1) age, (2) smoking status, body mass index, glycated hemoglobin, total cholesterol, and hypertension, and (3) ever use of hormone replacement therapy and age at menarche. We used two-sample Mendelian Randomization analysis to study whether there is a causal relationship between genetically proxied age at menopause and risk of stroke. Results: A total of 204,244 women were included (7,883 from EPIC-CVD [5,292 from the sub-cohort]; 196,361 from the UK Biobank). Pooled mean baseline age was 58.9 years (SD 5.8) and pooled mean age at menopause was 47.8 years (SD 6.2). Natural menopause occurred in 77.6% of all women. Over a median follow-up of 12.6 years (IQR 11.8, 13.3), 6,770 women experienced a stroke. In multivariable adjusted observational analyses, the pooled hazard ratios per five years younger age at

- menopause were 1.09 (95% C1: 1.07, 1.12) for stroke, 1.09 (1.06, 1.13) for ischemic
- 27 stroke, 1.10 (1.04, 1.16) for hemorrhagic stroke, 1.14 (1.08, 1.20) for intracerebral
- 28 hemorrhage, and 1.00 (0.84, 1.20) for subarachnoid hemorrhage. The Mendelian
- 29 Randomization analysis found no evidence for a causal relationship between
- 30 genetically proxied age at menopause and risk of any type of stroke.
- 31 **Conclusions:** Earlier age at menopause is associated with, but not causally related to
- 32 the risk of stroke.

Clinical Perspective

What is new?

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

- This analysis involves over 200,000 postmenopausal women and more than 6,000 incident stroke cases and investigates the observational association between age at menopause and various subtypes of stroke. Furthermore, a Mendelian Randomization analysis was conducted to study whether associations are causal or not.
- Earlier age at menopause was statistically significantly associated with a higher risk of stroke and its subtypes ischemic stroke, hemorrhagic stroke, and intracerebral hemorrhage. We found no statistically significant relationship between earlier or later age at menopause and risk of subarachnoid hemorrhage.
- The Mendelian Randomization analysis suggested no causal effect of genetically proxied age at menopause and risk of any type of stroke.

What are the clinical implications?

- Women with earlier age at menopause are at higher risk of stroke. The underlying reasons need to be further investigated.
- Our analysis suggested that earlier menopause per se does not cause stroke.
 For prevention and adequate treatment of stroke in women, a better understanding of the specific role of menopause and the mechanistic background that leads to higher risk of stroke is needed.

55	CI	Confidence interval
56 57	EPIC-CVD	European Prospective Investigation into Cancer and Nutrition-Cardiovascular Diseases
58	GWAS	Genome-wide association study
59 60	InterLACE	International Collaboration for a Life Course Approach to Reproductive Health and Chronic Disease Events
61	IQR	Interquartile range
62	IVW	Inverse variance weighted
63	HbA1c	Glycated hemoglobin
64	HR	Hazard ratio
65	HRT	Hormone replacement therapy
66	SD	Standard deviation
67	SNP	Single nucleotide polymorphism
68	UKB	UK Biobank

Introduction

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

Stroke is the second leading cause of death worldwide and was responsible for over six million deaths in 2019.¹ At a global level, the proportion of deaths caused by stroke is higher for women (12.5% in 2019) than for men (10.9% in 2019).² Women and men are also prone to different types of stroke. In a large-scale study in over nine million individuals, men had a higher risk of developing ischemic stroke, transient ischemic attack, and intracerebral hemorrhage, while women were at higher risk of subarachnoid hemorrhage.³ Women and men share several risk factors for stroke but the strengths of associations can differ between sexes.⁴ In addition, the relationship of various female-specific factors with cardiovascular risk has recently received increasing attention.⁵ The transition to menopause is predominantly defined by hormonal changes, and is accompanied by multi-faceted symptoms, such as sleep disturbances and vasomotor dvsfunction.⁶ Recent data suggest a relationship between earlier menopause and the risk of developing cardiovascular disease.^{7,8} A large-scale individual participant data meta-analysis of the International Collaboration for a Life Course Approach to Reproductive Health and Chronic Disease Events (InterLACE) consortium found a higher risk of developing stroke in women with earlier age at natural menopause.⁹ The hazard ratio (HR) for stroke was 1.72 (95% confidence interval [CI]: 1.43, 2.07) for women who experienced menopause before the age of 40 years compared to women who experience menopause at age 50 or 51 years. The majority of previous studies on age at menopause and risk of stroke focused on a combined stroke endpoint or analyzed broader categories of ischemic and hemorrhagic stroke rather than specific stroke subtypes.

Since associations between age at menopause and risk of stroke have been based on data from observational studies, which are prone to confounding, the causality of the associations is unclear. Importantly, although earlier menopause is also associated with a higher risk of coronary heart disease,9 we showed in a recent Mendelian Randomization analysis that this association is unlikely to be causal. ¹⁰ Furthermore, a Mendelian Randomization analysis based on publicly available results reported no significant causal relationship between genetically proxied age at natural menopause and risk of coronary artery disease or stroke. 11 Similarly, a recently published study demonstrated no causal association between age at natural menopause and risk of ischemic stroke, although a small number of genetic variants was used. 12 Whether this is also true for other types of stroke is still unclear. We conducted a large-scale analysis including 204,244 postmenopausal women from the UK Biobank (UKB) and European Prospective Investigation into Cancer and Nutrition-Cardiovascular Diseases (EPIC-CVD) study to quantify the observational association between age at menopause and different types of stroke, and to investigate whether these associations were likely to be causal by applying a

Methods

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

Study participants

Mendelian Randomization analysis.

In the present analysis, we included data from the UKB and EPIC-CVD study. Further details about these studies have been published previously.^{13–16} In brief, the UKB is a large-scale prospective study in the UK in which over 500,000 individuals aged 40 to 69 years were recruited between 2006 and 2010.^{13,14} The UKB was approved by the North West Multi-Centre Research Ethics Committee and all participants provided written informed consent. EPIC-CVD is a case-cohort study nested in the prospective

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

cohort study EPIC, which recruited more than 500,000 individuals between 35 and 70 years of age in 1992-2000 from 23 centers throughout Europe. 15-17 For the case-cohort study EPIC-CVD, a random sub-cohort was selected from the EPIC study for which a variety of biomarkers were obtained. In addition, EPIC-CVD includes all incident coronary heart disease and stroke events that occurred outside the sub-cohort. The EPIC study complies with the Declaration of Helsinki, and all participants gave written informed consent before participating. The study was approved by the local ethics committees of the participating centers and the Institutional Review Board of the International Agency for Research on Cancer (IARC, Lyon). For the current analysis, postmenopausal women free of history of stroke at study baseline were eliqible for inclusion. Furthermore, for EPIC-CVD, we excluded women with incident coronary heart disease and without incident stroke outside the sub-cohort due to the case-cohort design of study. **Figure 1** provides a flow chart on the selection of participants contributing to the current analysis. Of the 35,455 EPIC-CVD participants, we excluded 16,788 men, 632 women from French centers because follow-up for stroke was unavailable, 87 from Norway because important covariates were not measured, and 1,034 from Greece due to administrative constraints. Furthermore, we excluded 4,283 women with incident coronary heart disease outside the EPIC-CVD sub-cohort, 29 women with a history of stroke at baseline, and 4,719 women who were not postmenopausal, leaving 7,883 EPIC-CVD participants contributing to the current analysis. Of these 7,883 postmenopausal women, 5,292 belonged to the sub-cohort and 2,591 were stroke cases outside the sub-cohort (with 147 further stroke cases also belonging to the sub-cohort). Of the 502,412 individuals from UKB, 229,086 were excluded because they were male, 3,732 because they had a history of stroke at baseline, and 73,233 because they were not postmenopausal at baseline leaving 196,361 UKB participants contributing to our analysis. Consequently,

we included a total of 204,244 postmenopausal women from both studies in the

observational analysis.

Definition of menopause, age at menopause, and type of menopause

Women were defined as being postmenopausal if they fulfilled at least one of the following criteria: (1) experienced natural menopause (defined as stopping of periods in UKB and as reporting no menses for one year or longer due to natural menopause in EPIC-CVD), (2) had had a unilateral or bilateral ovariectomy in EPIC-CVD or bilateral ovariectomy in UKB, or (3) had had a hysterectomy. Moreover, where no information on menopausal status was provided, we defined women aged >54 years as postmenopausal, as suggested previously. Type of menopause was defined as surgical if a history of ovariectomy or hysterectomy had been reported and as natural, otherwise. Age at menopause was defined as age of a woman's last menstruation or, in case of a surgical menopause, the age at ovariectomy or hysterectomy.

Outcome definition

We analyzed a combined stroke endpoint including fatal and non-fatal ischemic and hemorrhagic stroke with ICD-10 codes I60, I61, I63, and I64. Furthermore, we analyzed the individual stroke endpoints ischemic stroke (I63, I64), hemorrhagic stroke (I60, I61), intracerebral hemorrhage (I61), and subarachnoid hemorrhage (I60). For UKB participants, September 30, 2021, was used as end of follow-up for stroke. In EPIC-CVD, end of follow-up for stroke varied between the centers ranging from 2003 to 2010. Time to event was defined as time to stroke, death, or end of follow-up, whichever occurred first. For the analysis of stroke sub-types, we censored individual stroke events against each other and defined time to stroke as time to the first individual stroke endpoint. For instance, if an individual experienced both ischemic and hemorrhagic stroke, we only analyzed the first stroke event that occurred during follow-

up. In case two types of stroke occurred on the same day, we gave preference to

ischemic stroke over intracerebral hemorrhage over other types of stroke.

Details about the assessment and definition of additional variables used in our

analyses are described in the **Supplementary Methods**.

Genetic data

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

We obtained individual-level imputed data on genetic variants from both EPIC-CVD and UKB. Genotyping in EPIC-CVD was performed using the Human Core Exome array, Illumina 660 Quad array, and Omni Exome Express array. 18 In the UKB, participants were genotyped with the Affymetrix UK BiLEVE Axiom array and the Affymetrix UKB Axiom Array. 14,19 Genotype imputation was performed using the Haplotype Reference Consortium for EPIC-CVD¹⁸ and the Haplotype Reference Consortium as well as the UK10K haplotype reference panel for the UKB²⁰. For the Mendelian Randomization analysis, to quantify genetically proxied age at menopause, we used genetic variants reported to be associated with age at menopause by a large-scale genome-wide association study (GWAS) for our instrumental variable. 11 A detailed selection process of the single nucleotide polymorphisms (SNPs) is described in the **Supplementary Methods**. Of the 290 SNPs identified by the GWAS, we excluded 124 SNPs because they were unavailable (n=63), palindromic (n=16), or rare with minor allele frequencies <0.1 (n=45), and used the remaining 166 SNPs to determine genetically proxied age at menopause in our main Mendelian Randomization analysis (see eFigure 3 and eTable 1). As shown in Figure 1, from the 204,244 postmenopausal women included in our observational analysis, we excluded 2,140 women from EPIC-CVD and 6,468 women from the UKB because data on the SNPs included in our analysis were unavailable,

leaving 195,636 women included in our Mendelian Randomization analysis.

Statistical analysis

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

Descriptive statistics

Summary statistics of continuous variables are provided as means and standard deviations (SDs) if normally distributed or as medians and interquartile ranges (IQRs), otherwise. Categorical variables are summarized as numbers and percentages. Pooled means across both cohorts were obtained from random-effects meta-analysis. To enhance comparability, we provide descriptive statistics including EPIC-CVD participants from the sub-cohort only.

Observational analyses

For the observational analysis, we estimated the association between age at menopause and incidence of stroke using Cox-regression analysis. For UKB, we implemented a Cox proportional hazards model. For EPIC-CVD, we additionally took into account the case-cohort design of the study by implementing Prentice-weighted Cox-regression analysis with robust standard errors.²¹ For both studies, we used age at baseline as the underlying time scale. We investigated the relationship between age at menopause and risk of stroke implementing age at menopause as a continuous variable and also by categorizing it as <40, 40 to <45, 45 to <50, 50 to <55, and ≥55 years, using 50 to <55 years at menopause as the reference category. When analyzing age at menopause as a categorical variable, we also obtained P-values for linear trends by treating the categorical variable as a continuous variable in our model. Furthermore, we present 95% CIs for each category using quasi variances to enhance the comparison between individual categories.²² When analyzing age at menopause as a continuous variable, we reported HRs per five years younger age at menopause. For graphical demonstration purposes and to assess non-linearity, we also analyzed age at menopause using restricted cubic splines with three knots at 45, 50, and 55

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

years of age at menopause using an age of 50 years at menopause as reference. We progressively adjusted our analysis for (1) age at baseline (Model 1), (2) smoking status (never, ex, current), body mass index (kg/m²), glycated hemoglobin (HbA1c, %), total cholesterol (mmol/L), and hypertension (yes, no) at baseline (Model 2), and (3) ever use of hormone replacement therapy (HRT) at baseline (yes, no) and age at menarche (years) (Model 3). For EPIC-CVD, we additionally stratified all models by country. Finally, we combined study-specific results using random-effects metaanalysis when including age at menopause as continuous variable, and multivariate random-effects meta-analysis²³ when analyzing it as categorical variable. We also used multivariate random-effects meta-analysis²³ to combine beta coefficients of the restricted cubic splines model. We imputed missing values using multiple imputation by chained equations with 14 datasets and 30 iterations (see Supplementary **Methods** for more details). We estimated HRs for risk of stroke per five years younger age at menopause across the following subgroups: use of HRT (ever vs never), type of menopause (surgical vs natural), smoking status (current, ex vs never), and age at baseline. We included age at menopause, the subgroup variable of interest, and a formal interaction term between age at menopause and the subgroup variable of interest into our model. In addition, we adjusted the models for the baseline variables age, smoking status, body mass index, HbA1c, total cholesterol, hypertension, ever use of HRT, and age at menarche, if appropriate. For illustrative purposes we categorized age at baseline into <60 vs ≥60 years. The P-value for interaction for age at baseline was obtained from a model in which age at baseline was included as a continuous variable. For EPIC-CVD, we additionally stratified the model by country. We obtained effect estimates in each study and combined them using multivariate random-effects meta-analysis.²³

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

For the effect of the genetic variants on age at menopause, we used the beta coefficients and standard errors reported by the GWAS published by Ruth et al. 11 without the UKB data in order to avoid sample overlap. We transformed beta coefficients and standard errors to reflect genetic effects per five years age at menopause to enhance comparability to our observational analysis. Then, we investigated the strength of our genetic instrument based on the F-statistic. For both EPIC-CVD and UKB, the F-statistic was calculated from linear regression including all genetic variants as independent variables and age at menopause as the dependent variable using the first imputed dataset and only including individuals from the subcohort for EPIC-CVD. Next, we estimated the effect of genetically proxied age at menopause and risk of different types of stroke using Cox-regression analysis with age as the underlying time scale. For UKB, we adjusted our model for age at baseline and the first 16 genetic principal components as suggested by Privé et al.²⁴ For EPIC-CVD, we adjusted our model for age at baseline, the first ten genetic principal components (as 16 were not available), and genotype array, stratified by country, and implemented Prentice-weighted Cox-regression.²¹ We obtained effect estimates and standard errors for the association of each SNP with risk of different types of stroke. Finally, we conducted the Mendelian Randomization analysis based on (1) the effect estimates of the association between the SNPs and risk of different types of stroke we obtained from the UKB and EPIC-CVD and (2) the GWAS summary effect estimates on the relationship between the SNPs and age at menopause using the R-package MendelianRandomization.²⁵ We applied standard inverse-variance weighted (IVW) regression to obtain the effect estimates for the association of genetically proxied age at menopause with risk of different types of stroke. We combined the effect sizes across studies using fixed-effect meta-analysis.

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

Randomization analysis methods including simple median regression, weighted median regression, and MR-Egger regression. Second, we conducted a leave-one-out analysis omitting each SNP in turn to identify whether one of the SNPs particularly drives the result. Third, to study the distribution of stroke-related and female-specific factors across genetically proxied age at menopause, we obtained a polygenic risk score by calculating a weighted sum of the SNPs used in our analysis, weighting each SNP with the corresponding summary effect size obtained from the GWAS. We divided the polygenic risk score into study-combined fifths (fifths were comparable between the two studies) and compared the variables smoking status, body mass index, HbA1c, total cholesterol, hypertension, ever use of HRT, and age at menarche, across the five categories. Fourth, we further investigated pleiotropy by implementing MR-PRESSO.²⁶ Fifth, to consider the effect of rare genetic variants, we excluded SNPs with minor allele frequencies <0.01 (n=8), rather than those with minor allele frequencies <0.1 as we did in our primary analysis. This sensitivity analysis included 203 SNPs, which are listed in eTable 1. Sixth, we additionally adjusted our Mendelian Randomization analysis for phenotypes associated with cardiovascular risk, i.e., smoking status, body mass index, HbA1c, total cholesterol, hypertension, ever use of HRT, and age at menarche. Statistical analyses were carried out using R 4.0.5 (The R Foundation, Vienna, Austria). All statistical tests were two-sided and P-values ≤0.05 were deemed as statistically significant.

Results

Study population

Baseline characteristics of the study participants are demonstrated in **Table 1**, separately for the EPIC-CVD sub-cohort and UKB, and pooled across both cohorts. Overall, mean age was 58.9 years (SD 5.8) at baseline and 47.8 years (SD 6.2) at menopause. Surgical menopause was reported by 22.4% of the participants. Mean age at surgical and natural menopause was 41.9 (SD 7.0) and 49.8 (SD 4.6), respectively. Moreover, 51.3% of the women had a history of hypertension, 33.3% of the women smoked previously, and 8.7% smoked currently. Half of the women reported to have used HRT during their lifetime.

Observational analysis

Over a median follow-up of 12.6 years (IQR 11.8, 13.3; 13.0 [10.8, 14.3] in EPIC-CVD and 12.6 [11.8, 13.3] in UKB), 6,770 women experienced a stroke. Of those, 5,155 were ischemic and 1,615 were hemorrhagic (976 intracerebral hemorrhages and 639 subarachnoid hemorrhages). Of the 6,770 strokes, 2,738 occurred in EPIC-CVD and 4,032 in UKB. Pooled results on the association of age at menopause with risk of stroke are provided in **Table 2** and **Figure 2**. Each five years younger at menopause was associated with a higher risk of total stroke (most adjusted HR 1.09 [95% CI: 1.07, 1.12]), ischemic stroke (1.09 [1.06, 1.13]), hemorrhagic stroke (1.10 [1.04, 1.16]), and intracerebral hemorrhage (1.14 [1.08, 1.20]). Age at menopause was not associated with the risk of subarachnoid hemorrhage (most adjusted HR 1.00 [0.84, 1.20] for each five years younger). Age at menopause was approximately log-linearly associated with the risk of stroke (P-value for trend <0.001), ischemic stroke (P-value for trend <0.001), hemorrhagic stroke (P-value for trend <0.002), and intracerebral hemorrhage (P-value for trend <0.001). For instance, compared to women who had experienced menopause

between 50 and <55 years, multivariable adjusted HRs for stroke were 1.42 (1.28, 317 318 1.56), 1.23 (1.14, 1.33), 1.10 (1.02, 1.19), and 0.96 (0.84, 1.10) in women who had 319 experienced menopause at ages <40, 40 to <45, 45 to <50, and ≥55 years, 320 respectively. Separate results for EPIC-CVD and UKB are shown eTable 2 and eTable 321 3, respectively. Results for all subtypes of stroke, except subarachnoid hemorrhage 322 (higher risk for younger age at menopause in UKB but not in EPIC-CVD), were highly 323 consistent between EPIC-CVD and UKB as demonstrated in **eFigure 1**. 324 eFigure 2 provides results of subgroup analyses for each individual stroke endpoint 325 according to age at baseline, smoking status, use of HRT, and type of menopause. 326 Age at baseline modified the association between age at menopause and total stroke 327 (P-value for interaction 0.010) and ischemic stroke (P-value for interaction 0.003) with 328 higher HRs for younger postmenopausal women. We did not find any statistically 329 significant modification across all other subgroups (all P-values >0.05). 330 **Mendelian Randomization analysis** 331 The F-statistics for the 166 SNPs included in our Mendelian Randomization analysis 332 were 1.31 (R²: 5.2%) in EPIC-CVD and 23.2 (R²: 2.0%) in UKB. 333 Results of the Mendelian Randomization analysis are provided in Figure 3 (see eTable 334 4 for study-specific results). In contrast to the observational analysis, the IVW 335 regression showed no evidence for a causal effect of age at menopause on stroke risk 336 (HR per five years younger genetically proxied age at menopause 0.95 [95% CI: 0.82, 337 1.09; P-value=0.445]), nor for any of the individual stroke endpoints ischemic stroke, 338 hemorrhagic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage (all P-339 values>0.05).

Sensitivity analyses

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

The results of the Mendelian Randomization analyses were similar when applying simple median, weighted median, and MR-Egger regression (see Figure 3 and eTable 4). Furthermore, leave-one-out analyses showed robust associations when excluding each SNP in turn (data not shown). The MR-Egger method did not show any evidence for pleiotropy (P-values of intercept >0.05, see Figure 3 and eTable 4). Furthermore, MR-PRESSO did not yield any SNPs that produced significant horizontal pleiotropy. After only excluding rare SNPs with minor allele frequencies <0.01 we again found no statistically significant relationship between genetically proxied age at menopause and risk of stroke as demonstrated in **eFigure 4**. Data on baseline patient characteristics across fifths of the polygenic risk score are provided in eTable 5 (see distribution across age at menopause categories in eTable 6). There appeared to be an association between genetically proxied age at menopause and hypertension and ever use of HRT. However, when we adjusted our Mendelian Randomization analysis for all phenotypes, the association between genetically proxied age at menopause and risk of different types of stroke remained statistically nonsignificant as shown in eFigure 5.

Discussion

In this large-scale analysis, we found an association between earlier age at menopause and higher risk of stroke, which was not likely to be causal according to Mendelian Randomization analysis.

Strengths and limitations

Our study has several strengths. First, we included a large sample of postmenopausal women in our observational analyses and more than 6,000 incident stroke events providing excellent statistical power to detect associations and the potential influence

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

of a variety of predefined, clinically relevant characteristics. Second, we investigated several subtypes of stroke including ischemic and hemorrhagic stroke and intracerebral and subarachnoid hemorrhage. Third, we meta-analyzed data from two large-scale studies and found highly consistent results for all stroke endpoints except subarachnoid hemorrhage, which may be explained by limited statistical power for this subtype. Fourth, we applied Mendelian Randomization analysis, a statistical method to study whether the results we found in our observational analyses were likely to be causal. Our analysis also has limitations. First, the EPIC-CVD and UKB studies had a different study design (case-cohort versus cohort study). To take this into account, we implemented Cox-regression with Prentice-weighting for EPIC-CVD. Second, the EPIC-CVD and UKB studies mainly include individuals of European ancestries (>95% for UKB), which limits the generalizability to other population groups. Of note, also the underlying GWAS focused on individuals of European ancestry. Consequently, more data on other populations are needed. Third, although we broadly harmonized the definition of menopause in EPIC-CVD and the UKB, it differed slightly between the studies as we did not have data on unilateral ovariectomy in the UKB. Fourth, menopausal status was missing for some women in the UKB and we estimated it based on age at baseline as suggested in previously published analyses on EPIC-CVD data.²⁷ However, this only affected a small proportion of study participants (approximately 1% in UKB). Fifth, as age at menopause was self-reported, our analyses may also be affected by non-differential misclassification, which could have led to attenuation of the association towards the null. Sixth, although stroke events were ascertained comprehensively, there may remain some misclassification of events. However, it has been demonstrated that positive predictive values for stroke events defined based on hospital or death certificates are usually high.²⁸ Furthermore, although we studied several types of stroke, stroke is a heterogeneous disease with

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

specific types of stroke. Seventh, Mendelian Randomization analysis relies on several assumptions. The first assumption is that the genetic variants are associated with the exposure variable, i.e., with age at menopause. We have used genetic variants published by a recent GWAS.¹¹ After harmonization, we included 166 SNPs in our instrumental variable that had a sufficiently high F-statistic (i.e., >10 as suggested by Staiger and Stock²⁹) for the UKB. In EPIC-CVD, the F-statistic was rather low indicating weak instrument bias, which is likely due to the lower sample size and large number of SNPs included (as the R² statistic was even higher in EPIC-CVD than in the UKB). However, as we applied a two-sample Mendelian Randomization analysis, weak instrument bias acts towards the null and will therefore be conservative and we also found no significant effect of genetically proxied age at menopause on any type of stroke in the UKB. Moreover, the GWAS we used to define genetically proxied age at menopause focused on natural age at menopause. Therefore, our Mendelian Randomization study only tests for a causal association of age at natural menopause with stroke risk, while in our observational study we also included women with surgical menopause. However, our observational subgroup analyses showed no statistically significant difference in effect sizes between women with natural or surgical age at menopause. The second assumption of a Mendelian Randomization analysis relies on the principle that the genetic variants are not associated with confounding factors. We studied this assumption by comparing the polygenic risk score created by the SNPs included in our instrumental variable across several potential confounding factors and could not exclude an association between the polygenic risk score and hypertension and ever use of HRT. However, when we adjusted the Mendelian Randomization analysis for all phenotypes related to cardiovascular risk, the association remained nonsignificant. The third assumption of a Mendelian Randomization analysis is that the

effect of the genetic variants on the outcome only goes through the exposure variable.

To investigate this assumption, we (1) conducted a Mendelian Randomization analysis using MR-Egger, which yielded no significant intercepts, suggesting no evidence of directional pleiotropy, and (2) implemented MR-PRESSO, which resulted in no pleiotropic SNPs that should be excluded from the analysis.

Comparison to previous observational studies

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

The results from our observational analysis on risk of total stroke are comparable to previous findings from individual studies including the Korean Heart Study, 30 the China Kadoorie Biobank,³¹ and the Nurses' Health Study³². The InterLACE consortium metaanalyzed data from over 300,000 women, whereby a large proportion of these data (61%) were from the UKB, leading to an overlap with our study sample. In analyses excluding data from the UKB, they also found an increased risk of developing stroke for women with younger age at menopause. 9 Similarly, earlier age at menopause was associated with higher risk of ischemic stroke in the Korean Heart Study³⁰ and Framingham Study.³³ A study in textile workers from China did not confirm this association.³⁴ However, in the InterLACE consortium, early menopause was related to higher risk of ischemic stroke, although these data included UKB as well.9 In our analysis, earlier menopause was also associated with a higher risk of hemorrhagic stroke. In contrast, two previous studies^{30,34} reported no significant association between age at menopause and risk of hemorrhagic stroke. This discrepancy is most likely due to limited statistical power, as within the InterLACE consortium, again including UKB, risk of hemorrhagic stroke was higher in women with earlier menopause. Finally, in our meta-analysis we found no significant relationship between age at menopause and risk of subarachnoid hemorrhage, unlike an investigation in the Nurses' Health Study that reported a higher risk of aneurysmal subarachnoid hemorrhage for women with early menopause.³⁵ Of note, our observational analysis in

the UKB also found women with earlier age at menopause to be at higher risk of subarachnoid hemorrhage. However, after meta-analyzing data from the UKB with EPIC-CVD, the pooled hazard ratios were no longer statistically significant. This could probably be due to limited statistical power in EPIC-CVD as already mentioned above.

Mendelian Randomization analysis

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

Our Mendelian Randomization analysis did not provide evidence that the associations found in observational analyses are likely to be causal. This finding is in line with a previous study on the relationship between reproductive aging and risk of coronary heart disease, which also found that genetically proxied reproductive aging had no causal effect on risk of coronary heart disease. 10 Furthermore, a Mendelian Randomization analysis relying on publicly available GWAS results reported no significant causal relationship between genetically proxied age at natural menopause and risk of coronary artery disease or stroke. 11 Similarly, a recently published Mendelian Randomization study, using fewer genetic variants, also reported that there is likely to be no causal link between age at natural menopause and risk of ischemic stroke. 12 It is, therefore, likely that residual confounding is present in the observational analysis even though most observational studies controlled for potential confounding factors by adjusting for a set of stroke-related risk factors and female-specific factors. Identifying such confounding factors could help to better understand the development and progression of cardiovascular disease in women and might provide clues for previously unknown factors associated with menopause as well as stroke.

Implications of the findings

Although our study did not find evidence of a potential causal relationship between age at menopause and risk of stroke, age at menopause may still be an important marker for cardiovascular disease in women as demonstrated in our observational analysis. Apparently, earlier age at menopause does not per se cause stroke but it captures an impact on the risk of developing stroke that may be determined by one or more confounding factors. This seems to hold for various types of stroke including both ischemic and hemorrhagic stroke. While there was a consistent association between earlier age at menopause and higher risk of intracerebral hemorrhage in both studies included in our meta-analysis, the relationship with higher risk of subarachnoid hemorrhage was only statistically significant in the UKB. As we were not able to account for the unknown factors driving the observational results in our analysis, further investigations are warranted. Several factors have been hypothesized to be responsible for the increased cardiovascular risk after menopause. One frequently discussed factor that has been speculated to have a cardioprotective effect in premenopausal women is estrogen.³⁶ However, it has been shown that the association between estradiol and risk of myocardial infarction attenuated upon adjustment of age and other cardiovascular risk factors.³⁷ Furthermore, when studying causal relations of age at menopause with different types of outcomes, associations appear to be specifically confounded when assessing cardiovascular risk as, for instance, genetically proxied age at menopause was causally related to risk of osteoporosis, fractures, and lung cancer. 12 Understanding the mechanisms that lead to the observational relationship between earlier menopause and higher risk of stroke may help close an important knowledge gap that could enable us to better understand sexdifferences in the development of stroke.

Conclusion

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

Earlier age at menopause is associated with, but not causally related to, the risk of stroke.

Acknowledgements

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

This research has been conducted using the UKB Resource (Application Number 29916). We are extremely grateful to all participants in UKB. This work was supported by core funding from the British Heart Foundation (RG/13/13/30194; RG/18/13/33946) and NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) [*]. EPIC-CVD was funded by the European Research Council (268834), the European Commission Framework Programme 7 (HEALTH-F2-2012-279233) and Novartis. We thank all EPIC participants and staff for their contribution to the study, the laboratory teams at the Medical Research Council Epidemiology Unit for sample management and Cambridge Genomic Services for genotyping, Sarah Spackman for data management, and the team at the EPIC-CVD Coordinating Centre for study coordination and administration. *The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The GWAS array was funded by the European Commission Framework Programme 7 (HEALTH-F2-2012-279233). Exomechip genotyping projects were funded by Pfizer and Merck. Where authors are identified as personnel of the International Agency for Research on Cancer / World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer / World Health Organization. Furthermore, we thank Bas B L Penning de Vries for valuable advice on the multiple imputation analysis.

Sources of Funding

514 This work was funded by the Austrian Science Fund (T 1253).

515 **Disclosures**

516 None.

517 Supplemental Material

- 518 Supplemental Methods
- 519 eTables 1-6
- 520 eFigures 1-5

521 References

- 522 1. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, Abbasi-
- Kangevari M, Abbastabar H, Abd-Allah F, Abdelalim A, et al. Global burden of
- 369 diseases and injuries in 204 countries and territories, 1990–2019: a
- 525 systematic analysis for the Global Burden of Disease Study 2019. *Lancet*.
- 526 2020;396:1204–1222. doi: 10.1016/S0140-6736(20)30925-9.
- 527 2. Institute for Health Metrics and Evaluation. GBD Compare Data Visualization.
- Seattle, WA: IHME, University of Washington web site.
- 529 https://vizhub.healthdata.org/qbd-compare/. Accessed July 21, 2022.
- 530 3. Vyas MV, Silver FL, Austin PC, Yu AYX, Pequeno P, Fang J, Laupacis A, Kapral
- MK. Stroke Incidence by Sex Across the Lifespan. *Stroke*. 2021;52:447–451. doi:
- 532 10.1161/strokeaha.120.032898.
- 533 4. Rexrode KM, Madsen TE, Yu AYX, Carcel C, Lichtman JH, Miller EC. The
- Impact of Sex and Gender on Stroke. Circ Res. 2022;130:512–528. doi:
- 535 10.1161/CIRCRESAHA.121.319915.
- 536 5. O'Kelly AC, Michos ED, Shufelt CL, Vermunt JV, Minissian MB, Quesada O,
- 537 Smith GN, Rich-Edwards JW, Garovic VD, El Khoudary SR, et al. Pregnancy and
- Reproductive Risk Factors for Cardiovascular Disease in Women. *Circ Res.*
- 539 2022;130:652–672. doi: 10.1161/CIRCRESAHA.121.319895.
- 540 6. Nelson HD. Menopause. *Lancet*. 2008;371:760–770. doi: 10.1016/S0140-
- 541 6736(08)60346-3.
- 542 7. El Khoudary SR, Aggarwal B, Beckie TM, Hodis HN, Johnson AE, Langer RD,
- Limacher MC, Manson JE, Stefanick ML, Allison MA. Menopause Transition and
- 544 Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A
- Scientific Statement From the American Heart Association. *Circulation*.
- 546 2020;142:e506-e532. doi: 10.1161/CIR.0000000000000912.

- 8. Peters SA, Woodward M. Women's reproductive factors and incident
- cardiovascular disease in the UK Biobank. *Heart.* 2018;104:1069–1075. doi:
- 549 10.1136/heartjnl-2017-312289.
- 550 9. Zhu D, Chung H-F, Dobson AJ, Pandeya N, Giles GG, Bruinsma F, Brunner EJ,
- Kuh D, Hardy R, Avis NE, et al. Age at natural menopause and risk of incident
- 552 cardiovascular disease: a pooled analysis of individual patient data. *The Lancet*
- 553 Public Health. 2019;4:e553-e564. doi: 10.1016/S2468-2667(19)30155-0.
- 10. Dam V, Onland-Moret NC, Burgess S, Chirlaque M-D, Peters SAE, Schuit E,
- Tikk K, Weiderpass E, Oliver-Williams C, Wood AM, et al. Genetically
- Determined Reproductive Aging and Coronary Heart Disease: A Bidirectional 2-
- sample Mendelian Randomization. *J Clin Endocrinol Metab.* 2022;107:e2952-
- 558 e2961. doi: 10.1210/clinem/dgac171.
- 11. Ruth KS, Day FR, Hussain J, Martínez-Marchal A, Aiken CE, Azad A, Thompson
- DJ, Knoblochova L, Abe H, Tarry-Adkins JL, et al. Genetic insights into biological
- mechanisms governing human ovarian ageing. *Nature*. 2021;596:393–397. doi:
- 562 10.1038/s41586-021-03779-7.
- 12. Lankester J, Li J, Salfati ELI, Stefanick ML, Chan KHK, Liu S, Crandall CJ,
- 564 Clarke SL, Assimes TL. Genetic evidence for causal relationships between age
- at natural menopause and the risk of ageing-associated adverse health
- outcomes. *Int J Epidemiol*. 2022. doi: 10.1093/ije/dyac215.
- 13. Allen N, Sudlow C, Downey P, Peakman T, Danesh J, Elliott P, Gallacher J,
- Green J, Matthews P, Pell J, et al. UK Biobank: Current status and what it means
- for epidemiology. *Health Policy and Technology*. 2012;1:123–126. doi:
- 570 10.1016/j.hlpt.2012.07.003.
- 14. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott
- P, Green J, Landray M, et al. UK biobank: an open access resource for

- identifying the causes of a wide range of complex diseases of middle and old
- age. *PLoS Med.* 2015;12:e1001779. doi: 10.1371/journal.pmed.1001779.
- 575 15. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, Charrondière UR,
- Hémon B, Casagrande C, Vignat J, et al. European Prospective Investigation
- into Cancer and Nutrition (EPIC): study populations and data collection. *Public*
- 578 Health Nutr. 2002;5:1113–1124. doi: 10.1079/PHN2002394.
- 16. Danesh J, Saracci R, Berglund G, Feskens E, Overvad K, Panico S, Thompson
- 580 S, Fournier A, Clavel-Chapelon F, Canonico M, et al. EPIC-Heart: the
- cardiovascular component of a prospective study of nutritional, lifestyle and
- biological factors in 520,000 middle-aged participants from 10 European
- 583 countries. *Eur J Epidemiol*. 2007;22:129–141. doi: 10.1007/s10654-006-9096-8.
- 17. Langenberg C, Sharp S, Forouhi NG, Franks PW, Schulze MB, Kerrison N,
- Ekelund U, Barroso I, Panico S, Tormo MJ, et al. Design and cohort description
- of the InterAct Project: an examination of the interaction of genetic and lifestyle
- factors on the incidence of type 2 diabetes in the EPIC Study. *Diabetologia*.
- 588 2011;54:2272–2282. doi: 10.1007/s00125-011-2182-9.
- 18. Zheng J-S, Luan J, Sofianopoulou E, Imamura F, Stewart ID, Day FR, Pietzner
- 590 M, Wheeler E, Lotta LA, Gundersen TE, et al. Plasma Vitamin C and Type 2
- 591 Diabetes: Genome-Wide Association Study and Mendelian Randomization
- Analysis in European Populations. *Diabetes Care*. 2021;44:98–106. doi:
- 593 10.2337/dc20-1328.
- 19. Collins R. What makes UK Biobank special? *Lancet*. 2012;379:1173–1174. doi:
- 595 10.1016/S0140-6736(12)60404-8.
- 596 20. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A,
- Vukcevic D, Delaneau O, O'Connell J, et al. Genome-wide genetic data on
- 598 ~500,000 UK Biobank participants. *bioRxiv*. 2017. doi: 10.1101/166298.

- 599 21. Onland-Moret NC, van der A DL, van der Schouw YT, Buschers W, Elias SG,
- van Gils CH, Koerselman J, Roest M, Grobbee DE, Peeters PHM. Analysis of
- case-cohort data: a comparison of different methods. *J Clin Epidemiol*.
- 602 2007;60:350–355. doi: 10.1016/j.jclinepi.2006.06.022.
- 603 22. Firth D. Quasi-variances. *Biometrika*. 2004;91:65–80. doi:
- 604 10.1093/biomet/91.1.65.
- 605 23. White IR. Multivariate Random-effects Meta-analysis. *Stata J.* 2009;9:40–56. doi:
- 606 10.1177/1536867X0900900103.
- 607 24. Privé F, Luu K, Blum MGB, McGrath JJ, Vilhjálmsson BJ. Efficient toolkit
- 608 implementing best practices for principal component analysis of population
- genetic data. *Bioinformatics*. 2020;36:4449–4457. doi:
- 610 10.1093/bioinformatics/btaa520.
- 611 25. Yavorska OO, Burgess S. MendelianRandomization: an R package for
- 612 performing Mendelian randomization analyses using summarized data. Int J
- 613 *Epidemiol.* 2017;46:1734–1739. doi: 10.1093/ije/dyx034.
- 614 26. Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal
- pleiotropy in causal relationships inferred from Mendelian randomization
- 616 between complex traits and diseases. *Nat Genet.* 2018;50:693–698. doi:
- 617 10.1038/s41588-018-0099-7.
- 618 27. Dam V, van der Schouw YT, Onland-Moret NC, Groenwold RHH, Peters SAE,
- Burgess S, Wood AM, Chirlaque M-D, Moons KGM, Oliver-Williams C, et al.
- Association of menopausal characteristics and risk of coronary heart disease: a
- pan-European case-cohort analysis. *Int J Epidemiol.* 2019;48:1275–1285. doi:
- 622 10.1093/ije/dyz016.
- 623 28. Woodfield R, Grant I, Sudlow CLM. Accuracy of Electronic Health Record Data
- for Identifying Stroke Cases in Large-Scale Epidemiological Studies: A

- Systematic Review from the UK Biobank Stroke Outcomes Group. *PLoS One*.
- 626 2015;10:e0140533. doi: 10.1371/journal.pone.0140533.
- 627 29. Staiger D, Stock JH. Instrumental Variables Regression with Weak Instruments.
- 628 Econometrica. 1997;65:557. doi: 10.2307/2171753.
- 30. Jung KJ, Kim M-R, Yun YD, Kim HC, Jee SH. Duration of ovarian hormone
- exposure and atherosclerotic cardiovascular disease in Korean women: the
- 631 Korean Heart Study. *Menopause*. 2016;23:60–66. doi:
- 632 10.1097/GME.0000000000000489.
- 633 31. Yang L, Lin L, Kartsonaki C, Guo Y, Chen Y, Bian Z, Xie K, Jin D, Li L, Lv J, et
- al. Menopause Characteristics, Total Reproductive Years, and Risk of
- 635 Cardiovascular Disease Among Chinese Women. Circ Cardiovasc Qual
- 636 Outcomes. 2017;10. doi: 10.1161/CIRCOUTCOMES.117.004235.
- 637 32. Ley SH, Li Y, Tobias DK, Manson JE, Rosner B, Hu FB, Rexrode KM. Duration
- of Reproductive Life Span, Age at Menarche, and Age at Menopause Are
- Associated With Risk of Cardiovascular Disease in Women. *J Am Heart Assoc.*
- 640 2017;6. doi: 10.1161/JAHA.117.006713.
- 33. Lisabeth LD, Beiser AS, Brown DL, Murabito JM, Kelly-Hayes M, Wolf PA. Age
- at natural menopause and risk of ischemic stroke: the Framingham heart study.
- 643 Stroke. 2009;40:1044–1049. doi: 10.1161/STROKEAHA.108.542993.
- 644 34. Gallagher LG, Davis LB, Ray RM, Psaty BM, Gao DL, Checkoway H, Thomas
- DB. Reproductive history and mortality from cardiovascular disease among
- women textile workers in Shanghai, China. *Int J Epidemiol*. 2011;40:1510–1518.
- 647 doi: 10.1093/ije/dyr134.
- 648 35. Lai PMR, Jimenez M, Du R, Rexrode K. Association of Reproductive Life Span
- and Age at Menopause With the Risk of Aneurysmal Subarachnoid Hemorrhage.
- 650 Neurology. 2022;98:e2005-e2012. doi: 10.1212/WNL.0000000000200222.

- 36. lorga A, Cunningham CM, Moazeni S, Ruffenach G, Umar S, Eghbali M. The
- protective role of estrogen and estrogen receptors in cardiovascular disease and
- the controversial use of estrogen therapy. *Biol Sex Differ*. 2017;8:33. doi:
- 654 10.1186/s13293-017-0152-8.
- 655 37. Peters SAE, Woodward M. Oestradiol and the risk of myocardial infarction in
- women: a cohort study of UK Biobank participants. Int J Epidemiol.
- 657 2021;50:1241–1249. doi: 10.1093/ije/dyaa284.
- 658 38. Geistanger A, Arends S, Berding C, Hoshino T, Jeppsson J-O, Little R, Siebelder
- 659 C, Weykamp C. Statistical methods for monitoring the relationship between the
- IFCC reference measurement procedure for hemoglobin A1c and the designated
- comparison methods in the United States, Japan, and Sweden. *Clin Chem.*
- 662 2008;54:1379–1385. doi: 10.1373/clinchem.2008.103556.
- 663 39. Peters T, Brage S, Westgate K, Franks PW, Gradmark A, Tormo Diaz MJ,
- Huerta JM, Bendinelli B, Vigl M, Boeing H, et al. Validity of a short guestionnaire
- to assess physical activity in 10 European countries. *Eur J Epidemiol*.
- 666 2012;27:15–25. doi: 10.1007/s10654-011-9625-y.
- 40. Guidelines for data processing analysis of the International Physical Activity
- Questionnaire (IPAQ) Short and long forms.
- 41. White IR, Royston P. Imputing missing covariate values for the Cox model. Stat
- 670 *Med.* 2009;28:1982–1998. doi: 10.1002/sim.3618.
- 42. Burgess S, White IR, Resche-Rigon M, Wood AM. Combining multiple imputation
- and meta-analysis with individual participant data. Stat Med. 2013;32:4499–
- 673 4514. doi: 10.1002/sim.5844.

Figure legends

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

Figure 1. Participant flow chart. *Excluded because follow-up for stroke was unavailable in French centers. †Excluded because important covariates were not measured in Norwegian centers. ‡Excluded because of administrative constraints. §Of these, 5,292 belonged to the sub-cohort and 2,591 were stroke cases outside the subcohort. Of these, 4,127 belonged to the sub-cohort and 1,616 were stroke cases outside the sub-cohort. Figure 2. Association of age at menopause and risk of stroke. Hazard ratios are adjusted for age, smoking status, body mass index, glycated hemoglobin, total cholesterol, hypertension, ever use of hormone replacement therapy, and age at menarche. Dots indicate point estimates and whiskers 95% confidence intervals for the categories <40, 40 to <45, 45 to <50, 50 to <55, and ≥55 years of age at menopause. Age at menopause from 50 to <55 years was used as reference category. Restricted cubic splines are based on three knots at 45, 50, and 55 years of age at menopause using an age of 50 years at menopause as reference. Figure 3. Mendelian Randomization analysis on genetically proxied age at menopause and risk of stroke. Hazard ratios are per five years younger genetically proxied age at menopause. Abbreviations: CI, confidence interval; IVW, inverse variance weighted.

694 Tables

695

696

697

698

699

Table 1. Baseline characteristics.

	Overall (n=201,653*)		EPIC-CVD (n=5,292*)		UK Biobank (n=196,361)		
Characteristic	Total No.	Mean ± SD, median [IQR], No. (% [†])	Total No.	Mean ± SD, median [IQR], No. (% [†])	Total No.	Mean ± SD, median [IQR], No. (%†)	
Stroke risk factors							
Age, years	201,653	58.9 ± 5.8	5,292	58.0 ± 6.4	196,361	59.9 ± 5.7	
Systolic BP, mmHg	189,007	137.1 ± 19.2	4,296	135.7 ± 20.0	184,711	138.4 ± 19.2	
Diastolic BP, mmHg	189,009	81.6 ± 9.9	4,296	82.0 ± 10.4	184,713	81.2 ± 9.9	
Hypertension	200,858	103,069 (51.3%)	5,245	2,362 (45.0%)	195,613	100,707 (51.5%)	
Body mass index, kg/m ²	200,628	26.8 ± 5.1	5,258	26.4 ± 4.6	195,370	27.3 ± 5.1	
Education	197,661		5,182		192,479		
Low		43,350 (21.9%)		2,026 (39.1%)		41,324 (21.5%)	
Medium		48,764 (24.7%)		615 (11.9%)		48,149 (25.0%)	
High		104,994 (53.1%)		1,988 (38.4%)		103,006 (53.5%)	
Smoking status	200,560		5,254		195,306		
Never		116,329 (58.0%)		3,071 (58.5%)		113,258 (58.0%)	
Ex		66,778 (33.3%)		1,092 (20.8%)		65,686 (33.6%)	
Current		17,453 (8.7%)		1,091 (20.8%)		16,362 (8.4%)	
Total cholesterol, mmol/L	188,029	6.2 ± 1.1	5,049	6.3 ± 1.2	182,980	6.0 ± 1.1	
HDL cholesterol, mmol/L	171,617	1.6 ± 0.4	5,049	1.6 ± 0.4	166,568	1.6 ± 0.4	
Triglycerides, mmol/L	187,916	1.4 [1.0, 2.0]	5,046	1.2 [0.8, 1.6]	182,870	1.4 [1.0, 2.0]	
HbA1c, %	186,905	5.6 ± 0.5	5,194	5.6 ± 0.7	181,711	5.5 ± 0.5	
Female-specific factors							
Age at menopause, years	189,095	47.8 ± 6.2	4,754	47.3 ± 6.4	184,341	48.4 ± 6.2	
Surgical menopause	201,653	45,193 (22.4%)	5,292	1,235 (23.3%)	196,361	43,958 (22.4%)	
Ever use of HRT	200,206	100,203 (50.0%)	4,722	1,733 (36.7%)	195,484	98,470 (50.4%)	
Ever use of OCP	200,736	155,303 (77.4%)	5,206	2,329 (44.7%)	195,530	152,974 (78.2%)	
Age at menarche, years	195,496	13.2 ± 1.6	5,156	13.4 ± 1.6	190,340	12.9 ± 1.6	

*Only participants of the EPIC-CVD sub-cohort were included in this table. †The denominator for all percentages was the number of postmenopausal women without missing values in the respective variable. Abbreviations: BP, blood pressure; OCP, oral contraceptive pill; HbA1c, glycated hemoglobin; HRT, hormone replacement therapy; IQR, interquartile range; SD, standard deviation.

Table 2. Association between age at menopause and risk of stroke in the EPIC-


CVD and UK Biobank studies (n=204,244).

Outcome/Age at	No. of	Model 1		Model 2		Model 3					
menopause (years)	cases	HR (95% CI)	P _{trend}	HR (95% CI)	P _{trend}	HR (95% CI)	P _{trend}				
Stroke											
<40	700	1.54 (1.36-1.75)		1.41 (1.27-1.58)		1.42 (1.28-1.56)					
40 to<45	891	1.31 (1.21-1.41)		1.24 (1.15-1.33)		1.23 (1.14-1.33)					
45 to <50	1,742	1.13 (1.05-1.23)	<0.001	1.10 (1.02-1.19)	< 0.001	1.10 (1.02-1.19)	<0.001				
50 to <55	2,623	1.00 (0.96-1.04)		1.00 (0.96-1.04)		1.00 (0.96-1.04)					
≥55	814	0.96 (0.83-1.10)		0.95 (0.83-1.10)		0.96 (0.84-1.10)					
per 5 years younger	6,770	1.12 (1.10-1.15)		1.10 (1.07-1.12)		1.09 (1.07-1.12)					
Ischemic stroke											
<40	534	1.59 (1.41-1.80)		1.43 (1.28-1.58)		1.43 (1.30-1.57)					
40 to<45	653	1.29 (1.15-1.45)		1.21 (1.07-1.36)		1.20 (1.07-1.36)					
45 to <50	1,350	1.16 (1.08-1.24)	<0.001	1.12 (1.05-1.20)	< 0.001	1.12 (1.05-1.20)	<0.001				
50 to <55	1,995	1.00 (0.95-1.05)		1.00 (0.95-1.05)		1.00 (0.94-1.06)					
≥55	623	0.95 (0.79-1.16)		0.94 (0.77-1.15)		0.95 (0.78-1.16)					
per 5 years younger	5,155	1.12 (1.10-1.15)		1.09 (1.07-1.12)		1.09 (1.06-1.13)					
Hemorrhagic stroke											
<40	166	1.37 (1.03-1.81)		1.32 (0.97-1.79)		1.33 (0.99-1.80)					
40 to<45	238	1.32 (1.03-1.69)		1.29 (1.00-1.67)		1.30 (1.01-1.68)					
45 to <50	392	1.08 (0.92-1.25)	0.007	1.06 (0.91-1.22)	0.036	1.06 (0.91-1.23)	0.022				
50 to <55	628	1.00 (0.93-1.08)		1.00 (0.92-1.09)		1.00 (0.92-1.08)					
≥55	191	0.97 (0.83-1.13)		1.00 (0.85-1.17)		0.99 (0.85-1.16)					
per 5 years younger	1,615	1.11 (1.06-1.17)		1.09 (1.03-1.16)		1.10 (1.04-1.16)					
Intracerebral hemorrh	age										
<40	102	1.52 (1.25-1.86)		1.50 (1.23-1.84)		1.53 (1.25-1.87)					
40 to<45	145	1.38 (1.16-1.65)		1.37 (1.15-1.64)		1.38 (1.16-1.65)					
45 to <50	224	1.02 (0.88-1.17)	<0.001	1.02 (0.88-1.17)	< 0.001	1.02 (0.89-1.17)	<0.001				
50 to <55	394	1.00 (0.90-1.11)		1.00 (0.90-1.12)		1.00 (0.90-1.12)					
≥55	111	0.84 (0.69-1.03)		0.85 (0.69-1.04)		0.85 (0.69-1.04)					
per 5 years younger	976	1.15 (1.09-1.21)		1.14 (1.08-1.20)		1.14 (1.08-1.20)					
Subarachnoid hemorr	hage										
<40	64	1.19 (0.71-2.00)		1.08 (0.59-1.98)		1.10 (0.62-1.96)					
40 to<45	93	1.20 (0.68-2.11)		1.15 (0.63-2.08)		1.15 (0.64-2.06)					
45 to <50	168	1.17 (0.94-1.45)	0.615	1.11 (0.94-1.31)	0.952	1.11 (0.93-1.32)	0.923				
50 to <55	234	1.00 (0.81-1.24)		1.00 (0.81-1.24)		1.00 (0.81-1.24)					
≥55	80	1.26 (0.96-1.65)		1.33 (0.96-1.84)		1.33 (0.96-1.83)					
per 5 years younger	620	1.03 (0.88-1.20)		1.00 (0.82-1.21)		1.00 (0.84-1.20)					

Model 1 is adjusted for age; Model 2 is additionally adjusted for smoking status, body mass index, HbA1c, total cholesterol, and hypertension; Model 3 is additionally adjusted for ever use of hormone replacement therapy and age at menarche. Confidence intervals for each age at menopause category are presented using quasi variances in order to enhance the comparison between individual categories. Age at menopause from 50 to <55 years was used as reference category. Ptrend indicates P-value for linear trend. Abbreviations: CI, confidence interval; HR, hazard ratio.

Figures

Figure 1. Participant flow chart.



*Excluded because follow-up for stroke was unavailable in French centers. †Excluded because important covariates were not measured in Norwegian centers. ‡Excluded because of administrative constraints. §Of these, 5,292 belonged to the sub-cohort and 2,591 were stroke cases outside the sub-cohort. ¶Of these, 4,127 belonged to the sub-cohort and 1,616 were stroke cases outside the sub-cohort.

715

716 717


718

719

720

721


722



Hazard ratios are adjusted for age, smoking status, body mass index, glycated hemoglobin, total cholesterol, hypertension, ever use of hormone replacement therapy, and age at menarche. Dots indicate point estimates and whiskers 95% confidence intervals for the categories <40, 40 to <45, 45 to <50, 50 to <55, and ≥55 years of age at menopause. Age at menopause from 50 to <55 years was used as reference category. Restricted cubic splines are based on three knots at 45, 50, and 55 years of age at menopause using an age of 50 years at menopause as reference.

menopause and risk of stroke.

724



Hazard ratios are per five years younger genetically proxied age at menopause. Abbreviations: CI, confidence interval; IVW, inverse variance weighted.

Age at menopause and the risk of stroke: Observational and Mendelian 729 Randomization analysis in 204,244 postmenopausal women 730 Tschiderer et al. 731

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

Assessment and definition of additional variables

In the UK Biobank, hypertension was defined as self-reported intake of antihypertensive medication or as having a systolic blood pressure >140 mmHg or a diastolic blood pressure >90 mmHg taking into account the average of two blood pressure measures taken a few moments apart. In EPIC-CVD, hypertension was defined as having a systolic blood pressure >140 mmHg, a diastolic blood pressure >90 mmHg, a self-reported history of hypertension, or as self-reported intake of antihypertensive medication. In both studies, body mass index was calculated by dividing weight in kg by height in m². In EPIC-CVD, low socioeconomic status was defined according to education, whereby no or primary schooling indicated low, secondary schooling indicated medium, and vocational schooling or university indicated high socioeconomic status. In the UK Biobank, socioeconomic status was defined according to thirds of the Townsend index, whereby values ≤-3.2 indicated low, >-3.2 and ≤-0.803 indicated medium, and >-0.803 indicated high socioeconomic status. Smoking was divided into never, ex, and current tobacco smoking. Lipid levels, including total cholesterol, high-density lipoprotein cholesterol, and triglycerides, were measured in serum samples at baseline on a Roche auto-analyzer at Stichting Huisartsen Laboratorium (Etten-Leur, The Netherlands) in EPIC-CVD and using a Beckman Coulter AU5800 platform in UK Biobank. Erythrocyte glycated hemoglobin (HbA1c) was measured using the Tosoh-G8 HPLC analyzer (Tosoh Bioscience, Japan) in EPIC-CVD and with Bio-Rad Variant II Turbo analyzers in the UK Biobank. In the UK Biobank, HbA1c was transformed from mmol/mol to % in using the formula [HbA1c in %] = 2.15 + 0.0915*[HbA1c in mmol/mol].³⁸ Physical activity was defined according to the Cambridge physical activity index in EPIC-CVD³⁹ and according to

the International Physical Activity Questionnaire (IPAQ) scoring protocol (short forms)⁴⁰ in the UK Biobank. In addition, ever use of hormone replacement therapy and ever use of oral contraceptive pill was self-reported in both studies. Finally, age at menarche was defined as age at first menstrual period, which was self-reported in both studies.

Multiple imputation of missing values

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

We imputed missing values using multiple imputation by chained equations with 14 datasets and 30 iterations. We included the following variables into our imputation high-density lipoprotein model: total cholesterol. cholesterol, apolipoprotein A1, apolipoprotein B, HbA1c, ever use of oral contraceptive pill, age at menarche, age at menopause, body mass index, history of diabetes mellitus, hypertension, ever use of hormone replacement therapy, smoking status, age at baseline, menopausal status, physical activity, type of menopause, incident stroke indicator, incident ischemic stroke indicator, incident hemorrhagic stroke indicator, incident intracerebral hemorrhage indicator, incident subarachnoid hemorrhage indicator, the Nelson-Aalen estimator for stroke (weighted by the sampling fraction for EPIC-CVD)⁴¹ for both the UK Biobank and EPIC-CVD. Additionally, we used the variables systolic blood pressure, diastolic blood pressure, and Townsend index for the UK Biobank and the variables center, country, and education for EPIC-CVD. In case the Pearson correlation coefficient between two predictors was higher than 0.7 or lower than -0.7, we only used the predictor with the higher correlation coefficient with the imputed variable. Furthermore, we implemented passive multiple imputation for the variable representing categories of age at menopause. For the meta-analysis we used within-study multiple imputation as suggested by Burgess et al.42, i.e., we

and applied random-effects meta-analysis to combine the individual study results.

Selection of SNPs

782

783

784

785

786

787

788

789

790

791

792

793

The selection process of SNPs included in the Mendelian Randomization analysis is demonstrated in eFigure 3. A detailed list of SNPs included is provided in eTable 1. Of the 290 SNPs identified by the GWAS, 11 we excluded (1) 63 SNPs because data were not available in EPIC-CVD; (2) 16 SNPs because they were palindromic and had an allele frequency between 0.3 and 0.7 obtained from either the summary data from the GWAS, within UK Biobank, or EPIC-CVD; and (3) 45 SNPs because they were rare with a minor allele frequency <0.1. Finally, we included 166 SNPs into our instrumental variable to genetically proxy age at menopause. Additionally, we checked whether the genetic variants were reported on the correct allele and harmonized the data accordingly.

795

eTable 1. Selection of SNPs.

SNPs obtained from	SNPs in ma	SNPs in sensitivity analysis after exclusion, because		
GWAS	data not available in EPIC-CVD	palindromic and allele frequency between 0.3 and 0.7	minor allele frequency <0.1	minor allele frequency <0.01
rs200448	rs200448	rs200448	rs200448	rs200448
rs9438982	rs9438982	rs9438982	rs9438982	rs9438982
rs12046563	rs12046563	rs12046563	rs12046563	rs12046563
rs57259875	rs57259875	rs57259875	rs57259875	rs57259875
rs112869704	rs112869704	rs112869704	rs112869704	rs112869704
rs12133213	-	_	_	-
rs11102802	rs11102802	rs11102802	rs11102802	rs11102802
rs72708144	rs72708144	rs72708144	_	rs72708144
rs2736609	rs2736609	rs2736609	rs2736609	rs2736609
rs41272475	rs41272475	rs41272475	_	_
rs371125724	_	_	_	_
rs11582336	rs11582336	rs11582336	rs11582336	rs11582336
rs1044595	rs1044595	rs1044595	rs1044595	rs1044595
		151044333	191044939	
rs7515939	rs7515939	-	_	-
rs4653680	_	_	_	_
rs7414807	rs7414807	rs7414807	rs7414807	rs7414807
rs1635506	rs1635506	rs1635506	rs1635506	rs1635506
rs72755295	rs72755295	rs72755295	_	rs72755295
rs851797	rs851797	rs851797	rs851797	rs851797
rs7539755	rs7539755	rs7539755	rs7539755	rs7539755
rs7779	rs7779	rs7779	_	rs7779
rs112866529	rs112866529	rs112866529	rs112866529	rs112866529
rs780088	rs780088	rs780088	rs780088	rs780088
rs12053063	rs12053063	rs12053063	rs12053063	rs12053063
rs10198789	rs10198789	rs10198789	rs10198789	rs10198789
rs67600408	rs67600408	rs67600408	_	rs67600408
rs17425341	rs17425341	rs17425341	rs17425341	rs17425341
rs76928871	rs76928871	rs76928871	rs76928871	rs76928871
rs2293269	rs2293269	-	-	-
rs199638788	132233203	_	_	_
rs62156756	rs62156756	rs62156756	rs62156756	rs62156756
		1302130730	1302130730	1302130730
rs4852777	rs4852777		-	-
rs67893326	rs67893326	rs67893326	rs67893326	rs67893326
rs59854799		-	-	
rs6727266	rs6727266	rs6727266	rs6727266	rs6727266
rs72827480	rs72827480	rs72827480	rs72827480	rs72827480
rs6430545	rs6430545	-	-	-
rs16830019	rs16830019	rs16830019	rs16830019	rs16830019
rs4668354	rs4668354	_	-	-
rs201478184	-	-	-	-
rs6719012	rs6719012	rs6719012	rs6719012	rs6719012
rs4972504	rs4972504	rs4972504	rs4972504	rs4972504
rs72934556	rs72934556	rs72934556	rs72934556	rs72934556
rs540836853	-	-	-	-
rs6736096	rs6736096	rs6736096	rs6736096	rs6736096
rs7558434	rs7558434	rs7558434	rs7558434	rs7558434
rs62193239	rs62193239	rs62193239	rs62193239	rs62193239
rs606920	rs606920	rs606920	rs606920	rs606920
rs12636454	rs12636454	rs12636454	rs12636454	rs12636454

rs62244773	rs62244773	able under a CC-BY 4.0 li	nternational license.	display the preprint in perpe
rs12487736	rs12487736	rs12487736	rs12487736	rs12487736
rs1264191	rs1264191	rs1264191	rs1264191	rs1264191
rs34675186	_	_	_	-
rs9968117	rs9968117	rs9968117	rs9968117	rs9968117
rs2885255	rs2885255	-	-	-
rs7610102	_	-	-	-
rs4679244	rs4679244	rs4679244	rs4679244	rs4679244
rs6793835	rs6793835	rs6793835	rs6793835	rs6793835
rs1545597	rs1545597	rs1545597	rs1545597	rs1545597
rs10154963	rs10154963	rs10154963	rs10154963	rs10154963
rs344018	rs344018	rs344018	rs344018	rs344018
rs72268838	_	-	-	_
rs10804920	rs10804920	rs10804920	rs10804920	rs10804920
rs979481644	_	-	-	_
rs13070791	rs13070791	rs13070791	rs13070791	rs13070791
rs3796624	rs3796624	rs3796624	rs3796624	rs3796624
rs2052160	rs2052160	rs2052160	rs2052160	rs2052160
rs190043078	_	_	_	_
rs6824237	rs6824237	rs6824237	rs6824237	rs6824237
rs2581458	rs2581458	rs2581458	rs2581458	rs2581458
rs76540949	_	_	_	_
rs12651246	rs12651246	rs12651246	rs12651246	rs12651246
rs7698733	-	_	_	_
rs145615497	rs145615497	rs145615497	_	rs145615497
rs6810489	rs6810489	rs6810489	rs6810489	rs6810489
rs35713108	_	_	_	_
rs112898082	rs112898082	rs112898082	rs112898082	rs112898082
rs2139178	rs2139178	rs2139178	rs2139178	rs2139178
rs9990489	rs9990489	rs9990489	rs9990489	rs9990489
rs274701	rs274701	rs274701	rs274701	rs274701
rs80167918	rs80167918	rs80167918	_	rs80167918
rs62356073	rs62356073	rs62356073	rs62356073	rs62356073
rs17206591	rs17206591	rs17206591	rs17206591	rs17206591
rs7728833	rs7728833	rs7728833	rs7728833	rs7728833
rs10070308	rs10070308	rs10070308	rs10070308	rs10070308
rs10477172	rs10477172	rs10477172	rs10477172	rs10477172
rs888694	rs888694	rs888694	_	rs888694
rs11744866	rs11744866	rs11744866	rs11744866	rs11744866
rs35813302	rs35813302	rs35813302	rs35813302	rs35813302
rs2241584	rs2241584	rs2241584	rs2241584	rs2241584
rs353478	rs353478	rs353478	rs353478	rs353478
rs76623841	rs76623841	rs76623841	-	rs76623841
rs9348724	rs9348724	rs9348724	rs9348724	rs9348724
rs72823382	rs72823382	rs72823382	rs72823382	rs72823382
rs4716056	rs4716056	rs4716056	rs4716056	rs4716056
rs9348752	rs9348752	rs9348752	-	rs9348752
rs6930435	rs6930435	rs6930435	rs6930435	rs6930435
rs3130040	rs3130040	rs3130040	-	rs3130040
rs4143333	rs4143333	rs4143333	_	rs4143333
rs2844466	rs2844466	rs2844466	rs2844466	rs2844466
rs9272211	-	-	-	-
rs9272982	-	-	-	-
rs7748483	rs7748483	rs7748483	_	rs7748483
rs9470134	-	-	-	-
rs515650	-	-	-	-
rs113967617	rs113967617	rs113967617	rs113967617	rs113967617
rs2147220	rs2147220	rs2147220	rs2147220	rs2147220
rs6569648	rs6569648	rs6569648	rs6569648	rs6569648
rs140381358	-	_	_	-
rs67149731	-	-	-	-

rs61065130	It is made avail	able under a CC-BY 4.0 li	nternational license.	
rs11767307	rs11767307	rs11767307	rs11767307	rs11767307
rs1826838	rs1826838	rs1826838	rs1826838	rs1826838
rs62445870	rs62445870	rs62445870	151020050	rs62445870
rs375846854	1502443670	1502445070	_	1502443670
rs10255049	rs10255049	rs10255049	rs10255049	rs10255049
rs2023778	rs2023778	rs2023778	rs2023778	rs2023778
rs2056726	rs2056726	rs2056726	rs2056726	rs2056726
rs2392836	rs2392836	rs2392836	rs2392836	rs2392836
rs4731541	rs4731541	_	-	_
rs112190116	-	-	-	-
rs2013	rs2013	rs2013	rs2013	rs2013
rs2061834	rs2061834	rs2061834	rs2061834	rs2061834
rs3750243	rs3750243	rs3750243	rs3750243	rs3750243
rs6473979	rs6473979	rs6473979	-	rs6473979
rs3735828	_	_	-	_
rs73264416	rs73264416	rs73264416	-	rs73264416
rs35529153	-	-	-	-
rs117431243	-	-	-	-
rs1467044	rs1467044	rs1467044	rs1467044	rs1467044
rs6470598	rs6470598	rs6470598	rs6470598	rs6470598
rs1476164	rs1476164	rs1476164	rs1476164	rs1476164
rs55873183	rs55873183	rs55873183	-	rs55873183
rs783562	rs783562	rs783562	rs783562	rs783562
rs4879656	rs4879656	rs4879656	rs4879656	rs4879656
rs10818873	rs10818873	rs10818873	-	rs10818873
rs138114862	_	-	-	-
rs10795520	rs10795520	rs10795520	rs10795520	rs10795520
rs74701710	rs74701710	rs74701710	_	rs74701710
rs10764106	rs10764106	rs10764106	rs10764106	rs10764106
rs10997819	rs10997819	rs10997819	rs10997819	rs10997819
rs10823203	rs10823203	rs10823203	rs10823203	rs10823203
rs1889921	rs1889921	rs1889921	rs1889921	rs1889921
rs7087644	rs7087644	rs7087644	-	rs7087644
rs74430332	rs74430332	rs74430332	_	rs74430332
rs10883451	rs10883451	rs10883451	rs10883451	rs10883451
rs7091889	rs7091889	rs7091889	rs7091889	rs7091889
rs11245450	rs11245450	rs11245450	rs11245450	rs11245450
rs728900	rs728900	-	-	-
rs6578283	rs6578283	rs6578283	rs6578283	rs6578283
rs7928823	_	-	-	-
rs34591978	_	_	-	-
rs11031006	rs11031006	rs11031006	rs11031006	rs11031006
rs10734411	rs10734411	rs10734411	rs10734411	rs10734411
rs10769315	rs10769315	rs10769315	rs10769315	rs10769315
rs7943302	rs7943302	rs7943302	rs7943302	rs7943302
rs10899493	rs10899493	rs10899493	rs10899493	rs10899493
rs11400191	_	_	_	_
rs60378595	_	_	_	_
rs148681796	rs148681796	rs148681796	_	rs148681796
rs10743271	_	_	_	_
rs2376898	rs2376898	rs2376898	rs2376898	rs2376898
rs77100210	rs77100210	rs77100210	_	rs77100210
rs61913600	rs61913600	rs61913600	rs61913600	rs61913600
rs10743724	rs10743724	rs10743724	rs10743724	rs10743724
rs10219645	-	_	_	-
rs2277339	rs2277339	rs2277339	rs2277339	rs2277339
rs28473132	-	-	-	-
rs7308068	rs7308068	rs7308068	rs7308068	rs7308068
rs75770066	rs75770066	rs75770066	- -	rs75770066
rs61069255	rs61069255	rs61069255	rs61069255	rs61069255

vnich was not certified	by peer review) is the aut	able under a CC BV 4.0 h	etornational license	aispiay the preprint in perpe
rs192638119	- It is made avail	able under a CC-BY 4.0 II	<u>liternational license</u> .	-
rs5800506	-	-	-	-
rs6490269	rs6490269	rs6490269	rs6490269	rs6490269
rs2942371	rs2942371	rs2942371	rs2942371	rs2942371
rs73413716	rs73413716	rs73413716	-	rs73413716
rs12825762	rs12825762	rs12825762	rs12825762	rs12825762
rs35067339	-	-	_	-
rs28416520	rs28416520	rs28416520	rs28416520	rs28416520
rs7318091	rs7318091	rs7318091	rs7318091	rs7318091
rs11571815	rs11571815	rs11571815	-	-
rs112727324	-	-	-	-
rs3736830	rs3736830	rs3736830	rs3736830	rs3736830
rs7322160	rs7322160	rs7322160	rs7322160	rs7322160
rs78566820	rs78566820	rs78566820	_	-
rs12868295	rs12868295	rs12868295	rs12868295	rs12868295
rs112097885	-	_	_	_
rs1713426	rs1713426	rs1713426	rs1713426	rs1713426
rs12879626	rs12879626	rs12879626	rs12879626	rs12879626
rs61488898	rs61488898	rs61488898	_	rs61488898
rs45547534	rs45547534	rs45547534	_	rs45547534
rs1969713	rs1969713	rs1969713	rs1969713	rs1969713
rs112326803	rs112326803	rs112326803	_	rs112326803
rs762643	rs762643	rs762643	rs762643	rs762643
rs1986616	rs1986616	rs1986616	rs1986616	rs1986616
rs71126035	131300010	-	-	_
rs375453823	_	_		_
rs9796	rs9796	_	_	
		- rc600016	rc600016	rc600016
rs689816	rs689816	rs689816	rs689816	rs689816
rs11071756	rs11071756	rs11071756	rs11071756	rs11071756
rs8025068	rs8025068	rs8025068	rs8025068	rs8025068
rs8035724	rs8035724	rs8035724	rs8035724	rs8035724
rs376442546	-	_	_	-
rs716886	rs716886	rs716886	rs716886	rs716886
rs62025270	rs62025270	rs62025270	rs62025270	rs62025270
rs12898357	rs12898357	rs12898357	rs12898357	rs12898357
rs28652789	rs28652789	rs28652789	rs28652789	rs28652789
rs4786509	rs4786509	-	-	-
rs17680522	rs17680522	rs17680522	rs17680522	rs17680522
rs8045589	rs8045589	-	-	-
rs9673473	rs9673473	_	_	_
rs2173885	-	_	-	-
rs11642909	rs11642909	rs11642909	rs11642909	rs11642909
rs11075466	rs11075466	rs11075466	rs11075466	rs11075466
rs10521305	rs10521305	rs10521305	-	rs10521305
rs8045027	rs8045027	rs8045027	rs8045027	rs8045027
rs200293726	-	_	_	_
rs12447180	rs12447180	rs12447180	rs12447180	rs12447180
rs502258	rs502258	rs502258	rs502258	rs502258
rs62054610	_	_	-	_
rs2108839	_	_	_	_
rs5030755	rs5030755	rs5030755	rs5030755	rs5030755
rs34856659	rs34856659	rs34856659	rs34856659	rs34856659
rs222859	-	_	_	_
rs569145577	_	_	_	_
rs8073434	rs8073434	rs8073434	rs8073434	rs8073434
rs1565920	rs1565920	rs1565920	rs1565920	rs1565920
rs111637825	rs111637825	rs111637825	_	rs111637825
rs799903	-	_	_	-
rs1815198	rs1815198	rs1815198	rs1815198	rs1815198
rs1991401	rs1991401	rs1991401	rs1991401	rs1991401
rs34609096	rs34609096	rs34609096	rs34609096	rs34609096

rs4800141	rs4800141 is made availa	able under a CC-BY 4.0 Ir	nternational license .	rs4800141
rs142239484	rs142239484	rs142239484	_	-
rs12605881	rs12605881	_	_	-
rs11542373	rs11542373	rs11542373	rs11542373	rs11542373
rs349306	rs349306	rs349306	rs349306	rs349306
rs56225015	rs56225015	rs56225015	rs56225015	rs56225015
rs12459191	rs12459191	rs12459191	rs12459191	rs12459191
rs147068659	_	-	_	_
rs148807049	rs148807049	rs148807049	rs148807049	rs148807049
rs10406053	rs10406053	rs10406053	rs10406053	rs10406053
rs191031532	_	_	_	_
rs2359811	rs2359811	rs2359811	rs2359811	rs2359811
rs11670032	rs11670032	rs11670032	rs11670032	rs11670032
rs424223	rs424223	rs424223	rs424223	rs424223
rs7249357	rs7249357	rs7249357	rs7249357	rs7249357
rs11349039	_	_	_	_
rs10409547	_	_	_	-
rs11668344	rs11668344	rs11668344	rs11668344	rs11668344
rs117146677	rs117146677	rs117146677	_	rs117146677
rs8109672	rs8109672	rs8109672	rs8109672	rs8109672
rs12461110	rs12461110	rs12461110	rs12461110	rs12461110
rs8101859	rs8101859	rs8101859	rs8101859	rs8101859
rs394448	rs394448	_	_	-
rs6054257	rs6054257	rs6054257	rs6054257	rs6054257
rs73078112	rs73078112	rs73078112	_	rs73078112
rs236117	rs236117	rs236117	rs236117	rs236117
rs16991615	rs16991615	rs16991615	_	rs16991615
rs148563363	rs148563363	rs148563363	_	_
rs746748	rs746748	rs746748	_	rs746748
rs58065489	rs58065489	rs58065489	rs58065489	rs58065489
rs11699793	rs11699793	rs11699793	rs11699793	rs11699793
rs483508	rs483508	rs483508	rs483508	rs483508
rs80047570	_	_	_	-
rs7266248	rs7266248	rs7266248	rs7266248	rs7266248
rs73307923	rs73307923	rs73307923	_	rs73307923
rs6011452	rs6011452	rs6011452	rs6011452	rs6011452
rs372721829	rs372721829	rs372721829	_	-
rs10854167	rs10854167	rs10854167	rs10854167	rs10854167
rs34978822	rs34978822	rs34978822	_	rs34978822
rs139337637	_	-	-	-
rs9975728	rs9975728	rs9975728	rs9975728	rs9975728
rs4148974	rs4148974	rs4148974	-	rs4148974
rs5746740	rs5746740	rs5746740	rs5746740	rs5746740
rs5754100	rs5754100	rs5754100	rs5754100	rs5754100
rs3838149	-	-	-	-
rs62237617	rs62237617	rs62237617	-	-
rs5762852	rs5762852	rs5762852	rs5762852	rs5762852
rs140353819	rs140353819	rs140353819	-	-
rs139906882	rs139906882	rs139906882	_	rs139906882
rs138430	rs138430	rs138430	rs138430	rs138430
rs2958663	rs2958663	_	_	_
rs2272805	rs2272805	rs2272805	rs2272805	rs2272805
rs148258173	-	-	-	-
rs2382759	-	-	-	-
rs62588628	-	_	-	-
rs5953379	-	-	-	-
rs5981360	_	_	_	_
rs3213462	-	-	-	-

Abbreviations: GWAS, genome-wide association study; SNP, single nucleotide polymorphism. For more details on the SNPs see the GWAS by Ruth et al.

796 797

CVD (n=7,883).

798

799

800

801

802

803

804 805

Outcome/Age at	No. of	Model 1		Model 2		Model 3	
menopause (years)	cases	HR (95% CI)	P _{trend}	HR (95% CI)	P _{trend}	HR (95% CI)	P _{trend}
Stroke							
<40	240	1.44 (1.20-1.73)		1.34 (1.10-1.63)		1.37 (1.12-1.67)	
40 to<45	340	1.30 (1.11-1.53)		1.24 (1.05-1.46)		1.25 (1.06-1.47)	
45 to <50	828	1.16 (1.05-1.29)	< 0.001	1.13 (1.02-1.26)	<0.001	1.14 (1.02-1.27)	<0.001
50 to <55	1,095	1.00 (0.92-1.08)		1.00 (0.92-1.09)		1.00 (0.92-1.09)	
≥55	235	0.88 (0.73-1.05)		0.87 (0.72-1.05)		0.88 (0.73-1.07)	
per 5 years younger	2,738	1.13 (1.08-1.18)		1.10 (1.05-1.16)		1.11 (1.06-1.16)	
Ischemic stroke							
<40	193	1.52 (1.24-1.85)		1.40 (1.13-1.73)		1.43 (1.15-1.77)	
40 to<45	270	1.34 (1.13-1.59)		1.27 (1.06-1.52)		1.28 (1.07-1.53)	
45 to <50	664	1.17 (1.04-1.30)	<0.001	1.14 (1.01-1.28)	<0.001	1.14 (1.02-1.28)	<0.001
50 to <55	874	1.00 (0.92-1.09)		1.00 (0.91-1.10)		1.00 (0.91-1.10)	
≥55	185	0.85 (0.70-1.04)		0.84 (0.69-1.03)		0.85 (0.70-1.05)	
per 5 years younger	2,186	1.14 (1.09-1.20)		1.12 (1.06-1.17)		1.12 (1.06-1.18)	
Hemorrhagic stroke							
<40	47	1.16 (0.84-1.60)		1.10 (0.80-1.53)		1.13 (0.81-1.57)	
40 to<45	70	1.15 (0.86-1.54)		1.13 (0.84-1.52)		1.13 (0.84-1.53)	
45 to <50	164	1.13 (0.95-1.35)	0.232	1.11 (0.92-1.33)	0.439	1.11 (0.93-1.33)	0.384
50 to <55	221	1.00 (0.86-1.16)		1.00 (0.85-1.17)		1.00 (0.85-1.17)	
≥55	50	0.98 (0.71-1.35)		1.02 (0.74-1.41)		1.02 (0.74-1.41)	
per 5 years younger	552	1.07 (0.99-1.16)		1.05 (0.97-1.14)		1.06 (0.97-1.15)	
Intracerebral hemorrha	age						
<40	30	1.31 (0.89-1.93)		1.32 (0.89-1.96)		1.34 (0.90-2.00)	
40 to<45	49	1.31 (0.92-1.88)		1.32 (0.92-1.90)		1.33 (0.93-1.91)	
45 to <50	91	1.01 (0.81-1.27)	0.050	1.03 (0.81-1.30)	0.054	1.03 (0.82-1.30)	0.047
50 to <55	147	1.00 (0.83-1.20)		1.00 (0.83-1.21)		1.00 (0.83-1.21)	
≥55	28	0.79 (0.52-1.20)		0.81 (0.53-1.22)		0.80 (0.53-1.22)	
per 5 years younger	345	1.15 (1.04-1.26)		1.14 (1.04-1.26)		1.15 (1.04-1.27)	
Subarachnoid hemorrh	nage						
<40	17	0.93 (0.53-1.61)		0.79 (0.44-1.41)		0.81 (0.45-1.45)	
40 to<45	21	0.88 (0.54-1.44)		0.83 (0.51-1.35)		0.84 (0.51-1.36)	
45 to <50	73	1.32 (1.03-1.71)	0.484	1.22 (0.94-1.58)	0.182	1.22 (0.94-1.58)	0.216
50 to <55	74	1.00 (0.77-1.29)		1.00 (0.77-1.30)		1.00 (0.77-1.30)	
≥55	22	1.44 (0.89-2.32)		1.56 (0.95-2.55)		1.55 (0.95-2.55)	
per 5 years younger	207	0.94 (0.82-1.09)		0.89 (0.77-1.04)		0.90 (0.78-1.05)	

Model 1 is adjusted for age; Model 2 is additionally adjusted for smoking status, body mass index, HbA1c, total cholesterol, and hypertension; Model 3 is additionally adjusted for ever use of hormone replacement therapy and age at menarche. Confidence intervals for each age at menopause category are presented using quasi variances in order to enhance the comparison between individual categories. Age at menopause from 50 to <55 years was used as reference category. Ptrend indicates P-value for linear trend. Abbreviations: CI, confidence interval; HR, hazard ratio.

Biobank (n=196,361).

806

807

808

809

810

811

812

813

Outcome/Age at	No. of	Model 1		Model 2		Model 3	
menopause (years)	cases	HR (95% CI)	P _{trend}	HR (95% CI)	P _{trend}	HR (95% CI)	P _{trend}
Stroke							
<40	460	1.63 (1.48-1.78)		1.46 (1.33-1.61)		1.45 (1.32-1.59)	
40 to<45	551	1.31 (1.20-1.42)		1.23 (1.13-1.34)		1.23 (1.13-1.33)	
45 to <50	914	1.11 (1.04-1.19)	<0.001	1.08 (1.01-1.16)	<0.001	1.08 (1.01-1.15)	<0.001
50 to <55	1,528	1.00 (0.95-1.05)		1.00 (0.95-1.05)		1.00 (0.95-1.06)	
≥55	579	1.02 (0.94-1.11)		1.01 (0.93-1.10)		1.01 (0.93-1.10)	
per 5 years younger	4,032	1.12 (1.09-1.15)		1.09 (1.07-1.12)		1.09 (1.06-1.12)	
Ischemic stroke							
<40	341	1.65 (1.48-1.84)		1.45 (1.30-1.61)		1.43 (1.28-1.59)	
40 to<45	383	1.25 (1.13-1.38)		1.16 (1.05-1.29)		1.15 (1.04-1.28)	
45 to <50	686	1.15 (1.06-1.24)	< 0.001	1.11 (1.02-1.20)	< 0.001	1.10 (1.02-1.19)	< 0.001
50 to <55	1,121	1.00 (0.94-1.07)		1.00 (0.94-1.07)		1.00 (0.94-1.07)	
≥55	438	1.04 (0.94-1.15)		1.02 (0.93-1.13)		1.02 (0.93-1.12)	
per 5 years younger	2,969	1.12 (1.09-1.15)		1.09 (1.06-1.12)		1.08 (1.05-1.11)	
Hemorrhagic stroke							
<40	119	1.56 (1.30-1.87)		1.52 (1.26-1.82)		1.53 (1.27-1.84)	
40 to<45	168	1.47 (1.26-1.71)		1.44 (1.24-1.68)		1.45 (1.24-1.69)	
45 to <50	228	1.03 (0.90-1.17)	<0.001	1.01 (0.88-1.15)	<0.001	1.01 (0.89-1.16)	<0.001
50 to <55	407	1.00 (0.90-1.11)		1.00 (0.90-1.11)		1.00 (0.90-1.11)	
≥55	141	0.96 (0.81-1.14)		0.97 (0.82-1.16)		0.97 (0.82-1.16)	
per 5 years younger	1,063	1.13 (1.08-1.18)		1.12 (1.07-1.17)		1.12 (1.07-1.18)	
Intracerebral hemorrh	age						
<40	72	1.62 (1.28-2.04)		1.57 (1.25-1.99)		1.60 (1.27-2.02)	
40 to<45	96	1.41 (1.15-1.73)		1.39 (1.14-1.70)		1.41 (1.15-1.72)	
45 to <50	133	1.02 (0.85-1.22)	<0.001	1.01 (0.85-1.20)	<0.001	1.01 (0.85-1.21)	<0.001
50 to <55	247	1.00 (0.88-1.14)		1.00 (0.87-1.14)		1.00 (0.87-1.15)	
≥55	83	0.86 (0.68-1.09)		0.87 (0.69-1.10)		0.87 (0.69-1.10)	
per 5 years younger	631	1.15 (1.08-1.22)		1.14 (1.07-1.21)		1.14 (1.07-1.21)	
Subarachnoid hemorr	hage						
<40	47	1.48 (1.10-1.98)		1.44 (1.07-1.93)		1.43 (1.06-1.92)	
40 to<45	72	1.55 (1.22-1.97)		1.52 (1.20-1.93)		1.52 (1.19-1.93)	
45 to <50	95	1.04 (0.85-1.27)	0.009	1.01 (0.83-1.24)	0.023	1.01 (0.83-1.24)	0.028
50 to <55	160	1.00 (0.85-1.17)		1.00 (0.85-1.17)		1.00 (0.85-1.18)	
≥55	58	1.12 (0.86-1.45)		1.15 (0.89-1.50)		1.15 (0.88-1.50)	
per 5 years younger	432	1.10 (1.02-1.19)		1.09 (1.01-1.18)		1.09 (1.00-1.17)	

Model 1 is adjusted for age; Model 2 is additionally adjusted for smoking status, body mass index, HbA1c, total cholesterol, and hypertension; Model 3 is additionally adjusted for ever use of hormone replacement therapy and age at menarche. Confidence intervals for each age at menopause category are presented using quasi variances in order to enhance the comparison between individual categories. Age at menopause from 50 to <55 years was used as reference category. Ptrend indicates P-value for linear trend. Abbreviations: CI, confidence interval; HR, hazard ratio.

menopause and risk of stroke.

814

815

816

817

Mathad/Qutaama	Overall		EPIC-CVI	EPIC-CVD		nk
Method/Outcome	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value
Stroke						
IVW	0.95 (0.82-1.09)	0.445	1.01 (0.72-1.41)	0.961	0.93 (0.80-1.09)	0.386
Simple median	1.00 (0.79-1.25)	0.982	1.00 (0.58-1.71)	0.993	1.00 (0.77-1.29)	0.983
Weighted median	0.98 (0.78-1.25)	0.893	1.11 (0.63-1.94)	0.717	0.96 (0.74-1.25)	0.750
MR-Egger	0.91 (0.66-1.27)	0.589	0.82 (0.38-1.77)	0.611	0.94 (0.65-1.34)	0.720
Intercept	1.00 (0.99-1.01)	0.816	1.01 (0.99-1.03)	0.556	1.00 (0.99-1.01)	0.984
Ischemic stroke						
IVW	0.98 (0.83-1.16)	0.805	1.08 (0.75-1.57)	0.672	0.96 (0.79-1.15)	0.627
Simple median	0.99 (0.77-1.28)	0.952	1.10 (0.62-1.97)	0.738	0.97 (0.72-1.29)	0.816
Weighted median	1.06 (0.81-1.39)	0.681	1.25 (0.68-2.29)	0.475	1.02 (0.75-1.38)	0.920
MR-Egger	1.01 (0.69-1.48)	0.960	0.87 (0.37-2.04)	0.744	1.05 (0.68-1.61)	0.827
Intercept	1.00 (0.99-1.01)	0.862	1.01 (0.98-1.03)	0.570	1.00 (0.99-1.01)	0.633
Hemorrhagic stroke						
IVW	0.85 (0.65-1.11)	0.230	0.77 (0.44-1.37)	0.377	0.87 (0.64-1.18)	0.374
Simple median	0.98 (0.64-1.52)	0.940	1.04 (0.42-2.58)	0.935	0.97 (0.59-1.59)	0.896
Weighted median	0.86 (0.55-1.34)	0.508	0.81 (0.31-2.15)	0.679	0.87 (0.53-1.44)	0.594
MR-Egger	0.68 (0.37-1.26)	0.219	0.70 (0.19-2.58)	0.593	0.67 (0.33-1.36)	0.268
Intercept	1.01 (0.99-1.02)	0.432	1.00 (0.97-1.04)	0.867	1.01 (0.99-1.03)	0.422
Intracerebral hemor	rhage					
IVW	0.92 (0.65-1.29)	0.617	0.90 (0.44-1.83)	0.770	0.92 (0.62-1.37)	0.683
Simple median	1.00 (0.57-1.76)	0.990	1.20 (0.37-3.89)	0.756	0.95 (0.50-1.80)	0.877
Weighted median	1.11 (0.62-2.00)	0.715	1.28 (0.38-4.26)	0.691	1.07 (0.55-2.08)	0.843
MR-Egger	0.97 (0.44-2.15)	0.935	0.74 (0.14-3.78)	0.713	1.05 (0.42-2.62)	0.911
Intercept	1.00 (0.98-1.02)	0.880	1.01 (0.97-1.05)	0.790	1.00 (0.97-1.02)	0.748
Subarachnoid hemo	rrhage					
IVW	0.75 (0.50-1.14)	0.184	0.61 (0.26-1.43)	0.252	0.81 (0.50-1.30)	0.377
Simple median	0.80 (0.41-1.55)	0.503	0.56 (0.15-2.08)	0.383	0.90 (0.42-1.95)	0.790
Weighted median	0.64 (0.33-1.24)	0.187	0.56 (0.14-2.19)	0.403	0.67 (0.31-1.43)	0.296
MR-Egger	0.40 (0.15-1.06)	0.066	0.62 (0.09-4.49)	0.640	0.35 (0.12-1.06)	0.064
Intercept	1.02 (0.99-1.04)	0.161	1.00 (0.95-1.05)	0.974	1.02 (1.00-1.05)	0.104

Abbreviations: CI, confidence interval; IVW, inverse variance weighted; HR, hazard ratio. HRs are per five years younger genetically proxied age at menopause.

polygenic risk score for age at menopause.

818

819

820

821 822

823

	Polygenic risk score*						
Characteristic	>0.393 to 1.12	>0.275 to 0.393	>0.172 to 0.275	>0.0537 to 0.172	-0.675 to 0.0537		
	n=39,128	n=39,127	n=39,127	n=39,127	n=39,127		
Stroke risk factors							
Age, years	58.8 ± 6.0	59.4 ± 5.8	59.3 ± 5.7	59.6 ± 5.6	59.8 ± 5.5		
Hypertension	19,466 (49.8%)	19,946 (51.0%)	20,012 (51.2%)	20,401 (52.2%)	20,771 (53.1%)		
Body mass index, kg/m ²	26.8 ± 5.1	26.8 ± 5.0	26.9 ± 5.0	26.6 ± 5.1	26.8 ± 5.1		
Smoking status							
Never	22,352 (57.4%)	22,544 (57.9%)	22,501 (57.8%)	22,596 (58.1%)	22,687 (58.3%)		
Ex	13,169 (33.8%)	12,935 (33.2%)	12,990 (33.4%)	12,868 (33.1%)	12,865 (33.1%)		
Current	3,419 (8.8%)	3,451 (8.9%)	3,435 (8.8%)	3,457 (8.9%)	3,371 (8.7%)		
Total cholesterol, mmol/L	6.2 ± 1.1	6.2 ± 1.1	6.2 ± 1.1	6.2 ± 1.1	6.2 ± 1.1		
HbA1c, %	5.6 ± 0.6	5.5 ± 0.5	5.5 ± 0.5	5.5 ± 0.6	5.6 ± 0.6		
Female-specific factors							
Ever use of HRT	20,485 (52.7%)	19,770 (50.8%)	19,355 (49.8%)	19,102 (49.1%)	18,527 (47.7%)		
Age at menarche, years	13.1 ± 1.6	13.2 ± 1.6	13.2 ± 1.6	13.2 ± 1.6	13.3 ± 1.6		

^{*}A higher polygenic risk score indicates a lower genetically proxied age at menopause. The denominator for all percentages was the number of postmenopausal women without missing values in the respective variable. Abbreviations: HbA1c, glycated hemoglobin; HRT, hormone replacement therapy.

of age at menopause.

824

825

826

827 828

	Age at menopause, years						
Characteristic	<40	40 to <45	45 to <50	50 to <55	≥55		
	n=17,461	n=23,508	n=45,778	n=77,933	n=24,415		
Stroke risk factors							
Age, years	55.4 ± 7.4	57.5 ± 6.9	58.4 ± 6.1	60.1 ± 4.9	62.3 ± 3.6		
Hypertension	8,848 (50.9%)	11,862 (50.7%)	22,156 (48.6%)	39,291 (50.6%)	14,111 (57.9%)		
Body mass index, kg/m ²	27.5 ± 5.5	27.0 ± 5.2	26.8 ± 5.1	26.7 ± 4.9	27.2 ± 5.0		
Smoking status							
Never	9,238 (53.1%)	12,848 (54.9%)	25,867 (56.7%)	46,662 (60.1%)	14,657 (60.3%)		
Ex	5,686 (32.7%)	7,943 (33.9%)	15,137 (33.2%)	25,549 (32.9%)	8,388 (34.5%)		
Current	2,463 (14.2%)	2,612 (11.2%)	4,590 (10.1%)	5,489 (7.1%)	1,270 (5.2%)		
Total cholesterol, mmol/L	6.0 ± 1.2	6.2 ± 1.2	6.2 ± 1.1	6.2 ± 1.1	6.3 ± 1.1		
HbA1c, %	5.5 ± 0.7	5.5 ± 0.6	5.6 ± 0.5	5.6 ± 0.5	5.6 ± 0.5		
Female-specific factors							
Ever use of HRT	11,733 (67.6%)	14,204 (60.8%)	22,551 (49.5%)	32,117 (41.4%)	11,898 (48.9%)		
Age at menarche, years	12.9 ± 1.8	13.0 ± 1.7	13.1 ± 1.6	13.2 ± 1.6	13.4 ± 1.6		

The denominator for all percentages was the number of postmenopausal women without missing values in the respective variable. Abbreviations: HbA1c, glycated hemoglobin; HRT, hormone replacement therapy.

Supplemental Figures

829

830

831


834

835

836

eFigure 1. Consistency of associations between age at menopause and risk of

various subtypes of stroke in EPIC-CVD and the UK Biobank.



Gray squares indicate results from EPIC-CVD and black dots indicate results from the UKB. The models were adjusted for age, smoking status, body mass index, glycated hemoglobin, total cholesterol, hypertension, ever use of hormone replacement therapy, and age at menarche. Abbreviations: CI, confidence interval; ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage.

stroke per five years younger age at menopause across several subgroups.

837

838

841

842


843

844

845

Subgroup Stroke	Level		Hazard ratio (95% CI)	P-value
Age	<60	-	1.13 (1.08-1.18)	0.010
•	≥60		1.08 (1.04-1.12)	
Smoking	Never		1.10 (1.05-1.17)	0.799
	Ex		1.09 (1.04-1.14)	
	Current		1.10 (1.04–1.16)	
Hormone replacement therapy	Never	-	1.10 (1.07-1.14)	0.582
Hormone replacement therapy	Ever	_	1.09 (1.06–1.12)	0.302
Type of managemen	Natural		. ,	0.498
Type of menopause		-	1.11 (1.07–1.14)	0.496
Out to to I	Surgical	-	1.09 (1.05-1.13)	
Subtotal		•	1.09 (1.07-1.12)	
Ischemic stroke	-00		4.42 (4.00, 4.40)	0.000
Age	<60		1.13 (1.08-1.19)	0.003
	≥60	-	1.08 (1.02-1.15)	
Smoking	Never	-	1.11 (1.02-1.20)	0.773
	Ex	-	1.08 (1.03-1.14)	
	Current		1.10 (1.04-1.16)	
Hormone replacement therapy	Never	-	1.09 (1.04-1.14)	0.995
	Ever	-	1.09 (1.05-1.13)	
Type of menopause	Natural		1.11 (1.05-1.17)	0.424
	Surgical		1.07 (1.03-1.12)	
Subtotal Hemorrhagic stroke		-	1.09 (1.06-1.13)	
Age	<60		1.12 (1.03-1.21)	0.902
	≥60		1.08 (1.01-1.16)	
Smoking	Never		1.10 (1.03-1.18)	0.943
- The state of the	Ex		1.10 (1.01–1.19)	0.0.0
	Current		1.09 (0.98-1.22)	
Hormone replacement therapy	Never		1.14 (1.06-1.22)	0.175
Hormone replacement therapy	Ever		, ,	0.175
Type of manageurs		T	1.06 (0.97-1.17)	0.024
Type of menopause	Natural	-	1.12 (1.04-1.20)	0.834
Outhordal	Surgical	T-	1.10 (0.99-1.24)	
Subtotal		_	1.10 (1.04-1.16)	
Intracerebral hemorrhage	-00		1.00 (1.10 1.00)	0.000
Age	<60	-•	1.20 (1.10-1.32)	0.238
	≥60		1.11 (1.05-1.19)	
Smoking	Never		1.13 (1.05-1.22)	0.691
	Ex		1.15 (1.05-1.27)	
	Current		1.16 (1.03-1.31)	
Hormone replacement therapy	Never		1.18 (1.09-1.27)	0.342
	Ever		1.12 (1.04-1.20)	
Type of menopause	Natural	 -	1.15 (1.06-1.25)	0.835
	Surgical	_ -	1.17 (1.06-1.28)	
Subtotal Subarachnoid hemorrhage		-	1.14 (1.08-1.20)	
Age	<60		1.02 (0.88-1.17)	0.935
	≥60		0.98 (0.75-1.27)	
Smoking	Never		1.02 (0.85-1.22)	0.638
3	Ex		0.97 (0.78-1.20)	
	Current		1.01 (0.79-1.28)	
Hormone replacement therapy	Never		1.05 (0.86-1.27)	0.258
	Ever		0.97 (0.78-1.19)	3.200
Type of menopause	Natural		1.02 (0.81-1.29)	0.656
Type of menopause	Surgical		, ,	0.000
Subtatal	ourgical	-	0.99 (0.73-1.34)	
Subtotal			1.00 (0.84-1.20)	
		0.75 1.0 1.25 1.	5	

Abbreviations: CI, confidence interval. P-values indicate P-values for interaction for the categorical variables smoking, hormone replacement therapy, and type of menopause. The P-value for interaction for age has been obtained from a model in which age was included as a continuous variable. All analyses were adjusted for the baseline variables age, smoking status, body mass index, glycated hemoglobin, total cholesterol, hypertension, ever use of hormone replacement therapy, and age at menarche, if appropriate.




Abbreviations: GWAS, genome-wide association study; SNP, single nucleotide polymorphism.

menopause and risk of stroke excluding very rare genetic variants only.

849

850

854



Abbreviations: CI, confidence interval; IVW, inverse variance weighted. Hazard ratios are per five years younger genetically proxied age at menopause. SNPs with minor allele frequencies <0.01 were excluded from this analysis and the analysis included 203 SNPs in total.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license. EFigure 5. Mendelian Randomization analysis on genetically proxied age at menopause and risk of stroke adjusted for phenotypes related to cardiovascular risk.

855

856


857

860

861

862

863



Abbreviations: CI, confidence interval; IVW, inverse variance weighted. Hazard ratios are per five years younger genetically proxied age at menopause. The analysis was additionally adjusted for smoking status, body mass index, glycated hemoglobin, total cholesterol, hypertension, ever use of hormone replacement therapy, and age at menarche. This analysis included 169,809 participants with complete data on all covariates (4,448 from EPIC-CVD and 165,361 from the UKB).